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Nicotinic acetylcholine receptors (nAChRs) play important roles in several 
neuro-pathologies for e.g. Alzheimer’s and Parkinson’s disease, pain, 
schizophrenia. Highly selective ligands help in understanding the distribution 
and physiological roles of nAChRs, many of which are not yet clear. Snake 
venom is an excellent source of such natural nAChR antagonists. In this study 
we have characterized a novel antagonist, drysdalin, from the venom of the 
Australian elapid snake Drysdalia coronoides. Drysdalin is a long-chain three-
finger toxin (3FTx) that has an unusually long C-terminal tail and is missing 
three key functional residues that are conserved in other long-chain α-
neurotoxins. Thus, our aim was to understand the activity of drysdalin and the 
roles of its distinct, non-conserved residues on its function as a nAChR 
antagonist. 
Drysdalin was recombinantly expressed and purified from E. coli followed by 
refolding. It showed neurotoxicity when injected in mice and a potent (3-fold 
less compared to α-bungarotoxin) irreversible postsynaptic activity on chick 
biventer cervicis muscle preparations. In electrophysiological experiments 
with nAChRs expressed in Xenopus oocytes, drysdalin showed nanomolar 
potency to mouse muscle and human α7 nAChRs. Cell-based fluorescence 
assays used to measure intracellular calcium release also showed nanomolar 
potency to human α7 nAChR. In radioligand binding assays, drysdalin has a 7-
fold higher affinity to Aplysia californica acetylcholine binding protein 
(AChBP) than to Lymnaea stagnalis AChBP. Thus, drysdalin binds to 
nAChRs and AChBP with high affinity, despite substitutions of key functional 
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residues, which would otherwise lead to decrease in affinity to nAChRs. In an 
attempt to increase the affinity of drysdalin towards nAChRs, those residues 
were mutated to the functionally important conserved residues of long chain α-
neurotoxins.  Three single mutants (R30F, L34R, and A37R), three double 
mutants (R30F,L34R, L34R,A37R; and R30F,A37R), one triple mutant 
(R30F,L34R,A37R) and one truncation mutant (with 20 residues removed 
from the C-terminal tail) were produced and compared to wild-type drysdalin. 
Functional characterizations of the mutants revealed that the R30F mutation 
and the truncation caused a significant reduction (> 5-fold) in binding activity 
on all receptors tested, indicating their importance in conferring drysdalin its 
function. The presence of the single mutation L34R and A37R does not cause 
a significant change (increase or decrease; < 5-fold) in the activity of 
drysdalin.  
Thus, this study has contributed to our understanding of three-finger toxins by 
demonstrating the functional importance of residues at the tip of loop-II and 
the C-terminal tail in this specific protein. This work also exhibits the 
importance of snake venoms as sources for the development of subtype-
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 Venom down under: Australian elapids  
Australia is home to at least 130 (including sea snakes) of the world’s 320+ 
species of elapid snake, one of the world’s most medically significant families 
of venomous snakes (Wilson and Swan, 2013). Despite this tremendous 
diversity, to date, the vast majority of toxinological research conducted on the 
venoms of Australian snakes has focused on just five of Australia's 26 genera. 
These five terrestrial genera (Acanthophis, Notechis, Pseudechis, 
Pseudonaja, and Oxyuranus) are considered the most medically significant of 
Australia’s venomous snakes (Hardy et al., 2014; Sutherland and Tibballs, 
2001), where medically significant snakes are defined as those that pose 
danger to humans through venomous bites. A further three genera 
(Austrelaps, Hoplocephalus, and Tropidechis) have received a moderate 
amount of research attention, while the remaining 18 genera of terrestrial 
elapid snakes have been almost completely neglected by toxinologists. As 
more species have been investigated, our knowledge of evolution and 
structure-function relationships of these toxin types has increased. An initial 
investigation of the venoms of some small Australian elapids has shown them 
to be equally as complex as those of their larger, better-investigated cousins 
(Pycroft et al., 2012). For this reason the small elapid fauna of Australia may 
be viewed as a rich and untapped bio resource, despite the fact that bites from 
many of these snakes are not considered medically significant.  
 Drysdalia coronoides: The white-lipped snake 
One of the rare genera of elapid snakes from south-eastern Australia 
(including the southern island of Tasmania) is Drysdalia, comprising three 
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species, D. coronoides, D. mastersii and D. rhodogaster. These are small 
(maximum length <50 cm), proteroglyphous (venomous, front-fanged) snakes. 
All are viviparous, feed primarily on lizards (Shine, 1981), and are secretive 
and rarely encountered. The most distinctive species 
within Drysdalia is D.coronoides, a relatively heavy-bodied, widely-
distributed and variably-coloured species, and the only one found in Tasmania. 
This snake is easily recognized by the thin white stripe running along its upper 
lip (continuing along the side of the head, fading out along the neck) and 
hence the name ‘white-lipped’ snake (Figure 1.1). D. mastersii and D. 
rhodogaster are more slender-bodied and are restricted to the south (mastersii) 
and east (rhodogaster) of mainland Australia. Also, recent molecular 
phylogenetic and dating analyses indicate that two highly divergent genetic 
lineages within Drysdalia coronoides occur in Tasmania (Dubey et al., 2010). 
 
 
Figure 1.1 Drysdalia coronoides, the white-lipped snake (photo courtesy: 
Mr. Michael Thow) 
 
 Snake venom and its composition 
Snake venoms are complex mixtures of proteins and peptides secreted from 
the venom gland (a modified vertebrate parotid salivary gland). Snake venom 
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contains a mixture of powerful proteins and peptides that have evolved to 
target receptors, ion channels or enzymes (Calvete, 2009), in addition to 
carbohydrates, nucleosides, lipids, and metal ions.  
Venom proteins interact with a wide variety of mammalian proteins and can 
disrupt the central and peripheral nervous systems, blood coagulation cascade, 
cardiovascular and neuromuscular systems, and homeostasis. In general, 
enzymes contribute to both immobilization and digestion of prey, while the 
non-enzymatic proteins mostly contribute to immobilization. 
 Enzymatic proteins from snake venom 
Snake venoms are rich in enzymes. The most common enzymes in snake 
venoms are (i) phospholipase A2s (PLA2s) (Kini, 1997; Kini, 2003); (ii) 
serine proteinases (Braud et al., 2000; Longo et al., 1985); (iii) snake venom 
metalloproteinases (SVMPs) (Calvete, 2005; Fox and Serrano, 2008b); (iv) 
acetylcholinesterase’s (AChEs) (Cousin and Bon, 1997; Frobert et al., 1997); 
(v) L-amino acid oxidases (L-AAOs) (Pawelek et al., 2000; Zuliani et al., 
2009); (vi) nucleotidases (5’-nucleotidases, ATPases, phosphodiesterase’s 
and DNases) and (vii) hyaluronidases (Dhananjaya and D’souza, 2010; Fox, 
2013; Girish and Kemparaju, 2007). These enzymes have varied structures, 







Table 1.1 Enzymatic proteins from snake venoms 
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 Non-enzymatic proteins from snake venom 
Non-enzymatic protein toxins exhibit lethal and debilitating effects as a 
consequence of neurotoxic, cardio toxic and tissue necrotizing effects, 
whereas enzymatic toxins induce various pharmacological effects, but are of a 
lower order of toxicity. So far, at least 16 families of the non-enzymatic 
families of venom proteins/peptides have been characterized. They are (i) 
three-finger toxins (3FTxs); (ii) serine-type proteinase inhibitors; (iii) snaclecs 
(C-type lectin-like and related proteins); (iv) nerve growth factors; (v) 
bradykinin potentiating peptides; (vi) natriuretic peptides; (vii) cysteine-rich 
secretory proteins (CRISPs) or helveprins; (viii) sarafotoxins; (ix) cobra 
venom factors; (x) vascular endothelial growth factors; (xi) waprins; (xii) 
vespryns; (xiii) veficolins; (xiv) myotoxins; (xv) AWIT peptides; and (xvi) 
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disintegrins. The members of each family exhibit remarkable similarities in 
structure but may differ in their pharmacological properties.  
 Three-finger toxins (3FTxs) 
This family of snake venom proteins is found in the venoms of elapines 
(cobras, kraits and mambas), hydrophiines (seasnakes), and colubrids (Pawlak 
et al., 2006; Pawlak et al., 2009) and have been reported in the transcriptomes 
of Viperinae and Crotalinae. The characteristic feature of all 3FTxs is their 
distinct protein fold – three β-stranded loops extending from a small, globular, 
hydrophobic core that is cross-linked by four or five conserved disulphide 
bridges (Ménez, 1998; Tsetlin, 1999). The three loops that project from the 
core region resemble three outstretched fingers of the hand (Figure 1.2), 
hence the name. Despite their overall structural similarity, they exhibit diverse 
functions with their active sites variably distributed on all the three loops of 
the toxin (Kini, 2002). They are further classified based on their 
pharmacological function and include neurotoxins, cardiotoxins, 





Figure 1.2 Three-finger toxin erabutoxin a 
The three β-sheeted loops outstretched from the central hydrophobic core 
formed by 4 disulphide bonds (shown in yellow). PDB 1QKD 
 
 Neurotoxins 
This family of 3FTxs interfere with the cholinergic transmission at various 
post-synaptic sites in the central and peripheral nervous systems, affecting 
neurotransmission (Changeux, 1990). Based on their receptor selectivity, they 
are classified as (i) curaremimetic or α-neurotoxins, which target muscle 
nAChRs; (ii) κ-toxins, which target neuronal nAChRs; and (iii) muscarinic 
toxins, which target various subtypes of muscarinic receptors (mAChRs). 
1.5.1.1 α-Neurotoxins 
The term α-neurotoxin was coined because this neurotoxin had the slowest 
migration under starch zone electrophoresis (Chang, 1999). The "α-" prefix 
subsequently came to connote any toxins with postsynaptic action. These 
toxins bind to the muscle (α1) nAChRs and inhibit acetylcholine from binding 
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to the receptor, thereby blocking neurotransmission (Lee, 1979). This causes 
paralysis of the skeletal muscles, which progresses to respiratory paralysis and 
finally death (Warrell et al., 1983a). In this respect, they imitate the toxic 
effects of the plant alkaloid d-tubocurarine and hence they are also known as 
curaremimetic neurotoxins.  They are polypeptides of 60-74 amino acid 
residues and are rich in disulphide bonds. They are broadly classified, based 
on their sequence length and number of disulphide bonds as short chain (60-
64 aa and four disulphide bonds) or long chain three-finger α-neurotoxin (66-
75 aa and five disulphide bonds). The structure-function relationship of these 
α-neurotoxins is well characterized by mutagenesis studies on both toxin and 
the receptor. 
Short-chain and long-chain α-neurotoxin 
The functional site of Erabutoxin a (Ebtx), a short-chain neurotoxin (SNTx) 
from the venom of the sea snake Laticauda semifasciata has been determined 
by site-directed mutagenesis approach (Tremeau et al., 1995).The functional 
site in the toxin spans over all the three loops consisting of three polar clusters: 
Glu7-Gln10 in loop I, which in interact with a hydrophobic cluster, Trp29-
Ile36 in loop II, Lys27-Glu38 and Arg33-Asp31 in loop II (Figure 1.3B). The 
only residue establishing the contact between loop I and loop II is Ser8. In 
loop III, however, Lys47 is the only functionally important residue. These 
critical residues are distributed on the bottom tips of all the three loops in the 
toxin. Similar mutation studies on α-cobratoxin (Cbtx), a long-chain 
neurotoxin (LNTx) from the venom of Naja kaouthia has delineated the 
functional site and mostly residue in loop II of the toxin (Figure 1.3C). This 
site consists of Lys23, Trp25, Asp27, Phe29, Arg33, Arg36 and K49 from 
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loop II and, Lys 49 and Phe65 belonging to loop III and C-terminal tail, 
respectively. It is important to note that the functional residues have 
structurally equivalent counterparts in both the toxins (SNTx and LNTx) lying 
mostly in loop II (Figure 1.3A). However, three major positions at which the 
functional sites of these two toxins vary are: Glu38 in Ebx is crucial for its 
activity but Asp38 in Cbtx is not; The longer loop I of Ebx but not of Cbtx, is 
critical for binding to the receptor; the extra fifth disulphide bond at the tip of 
loop II in Cbtx confers specificity to neuronal α7 nAChR (Servent et al., 
1997). 
 
Figure 1.3 Comparison of short- and long-chain α-neurotoxins 
(A) Sequence comparison of short-chain α-neurotoxin erabutoxin (Ebtx) and 
long-chain α-neurotoxin α-cobratoxin (Cbtx). The residues highlighted in 
green are functionally important residues. Cysteines are highlighted in yellow. 
(B), (C) Crystal structures of Ebtx a (PDB 1QKD) and Cbtx (PDB 2CTX) are 
shown for comparison. The side chains of the functionally important residues 




These toxins bind specifically to neuronal (α3β2) nAChR (Grant and 
Chiappinelli, 1985). Structurally they are similar to long-chain α-neurotoxins, 
with the fifth disulphide bridge located in the second loop. However, unlike 
long-chain neurotoxins, κ-neurotoxins exist as non-covalent homodimers. 
Functionally κ-neurotoxins also recognize α3β2 and α4β2 subtype but not to 
α1(Chiappinelli et al., 1996). They also interact with α7 nAChRs (Osipov et al., 
2008).  
1.5.1.3 Muscarinic toxins 
Muscarinic toxins (MTs) were originally purified from African mambas and 
characterized for their ability of inhibit the binding of selective muscarinic 
ligands to an enriched source of muscarinic receptors (Adem et al., 1988). 
According to their order of discovery and snake species they are named as 
MT1-MT7 coming from Dendroaspis angusticeps and MTα, MTβ and MTγ 
from the Dendroaspis polylepis (Karlsson et al., 1994). Muscarinic toxins 
isolated from mamba venom are 65-66 amino acids residues long with high 
sequence identity (more than 50%). Despite their similar primary and tertiary 
structures (3 finger fold of 3FTxs), MTs interact with the different muscarinic 
receptor subtypes with various pharmacological and functional profiles. Some 
muscarinic toxins act as agonists, whereas others act as antagonists on 
mAChR. For example, MT1 and MT2 have facilitatory effect in the memory 
test suggesting agonist role of these toxins in rat model (Jerusalinsky et al., 
1998). In contrast, MT3 from green mamba inhibits the binding of [3H] NMS, 
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a classical muscarinic radioligand, to native and cloned muscarinic receptors 
exhibiting the role of antagonist (Jerusalinsky et al., 2000). 
Muscarinic acetylcholine receptors (mAChRs) are G-protein coupled receptors 
(GPCRs) consisting of 5 subtypes namely, M1 to M5. These receptors are 
involved in various physiological processes and their dysfunction is related to 
various  neurological  disorders like schizophrenia, drug addiction, 
Alzheimer’s and Parkinson’s disease (Langmead et al., 2008) or  peripheral 
(chronic obstructive pulmonary disease, incontinence, overactive bladder, 
irritable bowel syndrome) diseases (Purves et al., 2001; Wess et al., 2007). 
Currently, all the drugs used for the treatment are non-selective antagonists 
which show affinity to more than one mAChRs. In spite of intensive research 
there is a lack of selective ligands that display sufficient levels of mAChRs 
subtype selectivity. The MTs atypical pharmacological profiles in terms of 
affinity, selectivity and mode of interaction (agonist, antagonist, allosteric 
modulator) have proved to be invaluable research and diagnostic tools to pave 
way for biomedical research on mAChRs. This may be attributed to the larger 
size of toxin compared to other allosteric ligands, which may cause the toxins’ 
contact surfaces with the receptor to extend to areas outside the allosteric site 
and include parts of the extracellular domains which are rather different in the 
various subtypes (Karlsson et al., 2000). 
1.5.1.4 Non-conventional neurotoxins 
Non-conventional toxins resemble the LNTxs, but differ in the presence of the 
fifth disulphide linkage in loop I instead of loop II (Figure 1.4) (Nirthanan et 
al., 2003b). They are also known as “weak toxins” due to their reduced 
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lethality as compared to other α-neurotoxins (Utkin et al., 2001). Candoxin is 
one of the well-studied nonconventional toxins isolated from the venom of 
Bungarus candidus (Malayan krait) (Nirthanan et al., 2002; Nirthanan et al., 
2003a). It produces readily and completely reversible blockage of chick 
biventer cervicis muscle preparations while irreversibly blocks rat neuronal α7 
nAChRs at nanomolar range. As mentioned previously, fifth pair of disulphide 
bond in loop II of long-chain neurotoxins is thought to be important for 
binding to the neuronal α7 receptors (Servent et al., 1997). But, in candoxin 
the fifth disulphide bond is located in loop I and not at the tip of loop II. This 
shows that even though non-conventional toxins and LNTxs share common 
scaffold there may be additional unidentified molecular targets recognized by 
non-conventional toxins. 
 
Figure 1.4 Comparison of non-conventional and long-chain α-neurotoxin 
 (A), (B) Crystal structures of Candoxin (PDB 1JGK) and Cbtx (PDB 2CTX) 
are shown for comparison. The disulphide bonds are shown in yellow. The 5th 
disulphide bond is present in Loop I of candoxin as compared to Loop II in 




 Acetylcholine receptors 
Acetylcholine receptors (AChRs) are integral membrane protein that responds 
to the endogenous neurotransmitter acetylcholine (ACh). They consist of 
consist of two major subtypes: the metabotropic muscarinic receptors and 
the ionotropic nicotinic receptors. Both share the property of being activated 
by ACh, and they are expressed by both neuronal and non-neuronal cells 
throughout the body (Albuquerque et al., 1995; Eglen, 2005). 
 Muscarinic Acetylcholine Receptors (mAChRs) 
The metabotropic receptors are second messenger, G protein-coupled seven-
transmembrane proteins. They are classically defined as being activated by 
muscarine, a toxin from the mushroom Amanita muscaria. Activation of 
muscarinic AChRs is relatively slow (milliseconds to seconds) and, depending 
on the subtypes present (M1–M5), they directly alter cellular homeostasis of 
phospholipase C, inositol trisphosphate, cAMP, and free calcium (Ishii and 
Kurachi, 2006). Thus they mediate slow metabolic responses to ACh via 
coupling to secondary messenger cascades. 
 Nicotinic Acetylcholine Receptors (nAChRs) 
Nicotinic acetylcholine receptors are ligand-gated ion channels (LGICs) which 
are directly linked to ion channels and does not use second 
messengers (as metabotropic receptors does). These receptors are sensitive to 
activation by nicotine (alkaloid from the plant family Solanaceae) and have 
ion channels whose activity is induced in the micro- to sub microsecond range. 
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Thus they mediate fast synaptic neurotransmission. These are one of the best 
characterized receptors. 
1.6.2.1 Structure 
These nAChRs belong to the Cys-loop superfamily of LGICs, that also include 
γ-amino butyric acid (GABA) type-A and -C,  5-hydroxytryptamine type 3 (5-
HT3), and glycine receptors (Karlin, 1993). The nAChRs are homo- or 
heteromeric pentameric assemblies of structurally related subunits, 
surrounding a central aqueous pore. These receptors gate the flux of either 
cations like K+, Na+ and Ca2+ (nAChRs and 5-HT3) or anions such as Cl- and 
HCO3- (GABAA/C and glycine receptors).  
To date, 17 subunits of nAChRs have been cloned. They have been divided 
into muscle-type (α1, β1, δ, γ and ε) and neuronal (α2-α10 and β2-β4) 
subunits (Lukas et al., 1999). On the basis of gene structures and protein 
sequence similarities, the nAChR subunits are grouped into four subfamilies 
(I-IV), with subfamily III further divided into three tribes (Figure 1.5). 
 
 
Figure 1.5 The nAChR family with its four subfamilies of subunits and a 





 These nAChR subunits are 500-600 aa residues long and can be divided into 2 
regions; a conserved extracellular NH2-terminal domain of ~210 amino acid 
residues and a transmembrane domain composed of 4 transmembrane α-
helical segments of ~20 residues, M1-M4, separated by alternating 
intracellular and extracellular loops and a short extracellular  COOH-terminal. 
These 2 regions of all the subunits assemble to create the N-terminal domain 
(NTD) and ion channel domain (ICD) of the pentameric nAChR receptor 
(Figure 1.6). 
All the subunits, in the first extracellular domain, have of a cysteine-loop 
(Cys-loop) defined by two cysteine’s (Cys) that in the mammalian subunits are 
separated by 13 intervening amino acids. The 17 subunits are also classified 
(into α- and non-α subunits) based on the presence of a Cys-Cys pair (residues 
191–192 in Torpedo α1) near the entrance to M1. The Cys-Cys pair is required 
for agonist binding (Karlin et al., 1986) and its presence designates the subunit 





Figure 1.6 Topology of the single nAChR subunit 
The two regions involved in the formation of the NTD and ICD of the 
pentameric nAChR are indicated. The 10 β-strands and the loops between in 
the N-terminal domain are numbered according to the AChBP X-ray structure 
(Brejc et al., 2001). The disulphide bond between two cysteine’s in creating 
the hallmark “Cys-loop” between β6 and β7 is shown in gray. Figure 









Based on their major site of expression, nAChRs are subdivided into muscle 
or neuronal subtypes. 
1.6.2.2 Muscle nAChRs 
Muscle nAChRs are found in the vertebrate skeletal muscle system, localized 
postsynaptically at the neuromuscular junction, where they mediate the 
neurotransmission. They consist of five subunits: α1 and 4 non-α subunits 
named β1, δ, γ (ε in foetus). These subunits organized in a clockwise 
α1(γ/ε)α1β1δ arrangement to form a functional receptor, wherein ACh binds 
to two orthosteric sites located at α1-γ and α1-δ interfaces of the receptor 
complex (Figure 1.7). Binding of ACh induces conformational changes, 
predominantly in the α1 subunits, which are communicated to the 
transmembrane region, causing channel opening (Unwin et al., 2002). 
1.6.2.3 Neuronal nAChRs  
The numerous neuronal nAChRs are distributed at the pre- and post-synaptic 
sites in autonomic ganglia and in cholinergic neurons throughout the CNS, 
where they are involved in a number of processes connected to cognitive 
functions, learning and memory, arousal, reward, motor control, and analgesia 
(Paterson and Nordberg, 2000; Sher et al., 2004).  
The 12 (α2-α10 and β2-β4) neuronal nAChR subunits can form a plethora of 
different nAChR subtypes (Figure 1.7) characterized by dramatically different 
characteristics in terms of ligand pharmacology, activation and desensitization 




Figure 1.7 Various subtypes of nicotinic acetylcholine receptors (nAChRs) 
The top panel shows the muscle nAChRs formed by α1, β, δ, γ/ε subunits. The 
bottom panel shows the neuronal nAChRs formed by α, β subunits. The ACh 
binding site at the subunit interface is shown as a white arrow. Figure adopted 
from (Paleari et al., 2009) 
 
 Acetylcholine binding protein (AChBP) 
Acetylcholine binding protein was first identified in the glia of the fresh water 
snail Lymnaea stagnalis (Ls) (Smit et al., 2001). It is secreted, in response to 
the presynaptic release of ACh, into the synaptic cleft and modulates the 
cholinergic transmission. The mature AChBP is 210 residues long and forms a 
stable soluble homopentamer, but lacks the transmembrane and intracellular 
domains of typical nAChRs. It aligns with the N-terminal domains of 
pentameric LGICs. AChBP is most closely related to the α-subunits of the 
nAChRs. Nearly all residues that are conserved within the nAChR family are 
present in AChBP, including those that are relevant for ligand binding (Figure 
1.8) (Smit et al., 2001). Moreover, AChBP binds known nAChR agonists and 
competitive antagonists such as acetylcholine, nicotine, d-tubocurarine, 
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methyllycaconitine, lobeline, epibatidine, α-conotoxin and α-bungarotoxin 
(Smit et al., 2001). Therefore, AChBP can be used as an example of the N-
terminal domain of the α-subunit of nAChRs. Two other AChBPs were 
identified from salt water snail Aplysia californica (Ac) and fresh water snail 
Bulinus truncatus (Bt). 
 
Figure 1.8 Sequence alignment of AChBP 
(A) Structural alignment of the subunit sequences of Ac-AChBP and Ls-
AChBP (Smit et al, 2001) with those of the human α1 and α7 LBDs (LGIC 
database). Secondary structure elements are indicated. The bar and open 
circles above the Ac-AChBP sequence indicate the loop C tip and hinge 
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regions, respectively. The solid circle denotes the glycosylated Asn74. Ac-
AChBP residues whose side chains interact within 4.5A°with all four ligands 
are on a gray background. Residues specific for the nicotinic antagonists, a-
conotoxin ImI and MLA, are on a red and green background and those specific 
for the nicotinic agonists, LOB and EPI, on an orange and a blue background, 
respectively. (B) Schematic view of the organic ligands, MLA (the 
lycoctonine ring is at the top and the N ethylpiperidine ring at the bottom), 
LOB and EPI. Top right: sequence and disulphide bonding of a-conotoxin ImI; 
the star denotes C-terminal amidation.  
Adopted from (Corringer, 1998) 
 Crystal structure of AChBP 
Though there are many crystal structures of Ls-AChBP co-crystalized with 
different agonists and antagonists are available, recently it was crystalized 
with ACh (Figure 1.9A) (Olsen et al., 2014). This is the first structure of 
acetylcholine in a binding pocket containing all five aromatic residues 
conserved in all mammalian nAChRs. The ligand-receptor interactions are 
mainly in the aromatic box which is formed from four (Tyr89, Trp143, 
Tyr185, Tyr192) aromatic resides on the principal side. Besides these 
interactions on the principal side, we observe a cation-π interaction between 




Figure 1.9 Crystal structure of Ls-AChBP bound to ACh 
(A) Top-view of a cartoon representation of the structure of Ls-AChBP 
pentamer with an ACh molecule bound in each interface (PDB 3WIP). The 
interface between 2 subunits with the ACh bound is circled. ACh is shown as 
spheres. (B) The ligand binding core formed by aromatic residues from the 
principal face (light pink) and complementary face (green) 
 
Crystal structure of long chain α-neurotoxins with nAChRs 
α- Bungarotoxin co-crystal structures with muscle and human α7-nAChRs 
have given insights in to the toxin receptor interaction sites. X-ray structure of 
the extracellular ligand binding domain (LBD) of the muscle nAChR α1 
subunit in complex with α-bungarotoxin was determined at a resolution of 
1.94 A° (Figure 1.10A) (Dellisanti et al., 2007). X-ray structure of α-
bungarotoxin bound to a chimera of human α7 LBD/AChBP was determined 
(Sun et al., 2013). In both these crystal structures the ligand binding pocket is 
seen to be a hydrophobic aromatic box, where the Phe32, Arg36 (Bgtx) form a 
cation-π stack and interact with the aromatic residues of the receptor. The 
other residue Val39 has hydrophobic interaction with other hydrophobic 




Figure 1.10 Crystal structure of Bgtx with nAChR  
The figure shows (A) Bgtx (orange) complex with the extracellular binding 
domain of mouse α1 subunit (pale green), (B) 5 molecules of complex with 
chimera of human α7 LBD/AChBP (pale green). 
 
 Aim and the scope of this thesis 
Little information about the distribution and function of the plethora of 
nicotinic acetylcholine receptors is known. Snake venom components are a 
good source of novel nAChR antagonists. This study describes the 
characterization of a one such novel nAChR antagonist from the snake 
Drysdalia coronoides and an attempt was made to increase its potency. 
To accomplish these following were the objectives of the study: 
1. To characterize the activity of drysdalin 
• Recombinant expression, purification, refolding of His-tagged 
drysdalin 
• Effect of drysdalin in a biological system (mice) 
• Site of action of drysdalin: Pre- or post-synaptic or myotoxic 
2. Interaction with various nAChRs 
• Interaction with mouse muscle and human α7 nAChR 
• Effect on Ca2+ influx in cells 
• Test the binding to AChBP 













Recently, a complementary “-omics” approach combining transcriptomics and 
proteomics has been employed in order to understand the complex mixture of 
snake venom, to identify low-abundance toxins, and to discover novel protein 
families in snake venom (Fox and Serrano, 2008a; Zelanis and Keiji Tashima, 
2014). For example new families of snake venom proteins like veficolins 
(OmPraba et al., 2010) and waprins (Torres et al., 2003) were identified with 
this approach. 
These techniques are particularly useful in understanding the venom 
composition of low venom yielding and rare snakes such as Drysdalia 
coronoides, which yields, on average, 2-3 mg of venom per milking. A partial 
cDNA library was obtained from the venom gland of D. coronoides along 
with proteomics of its crude venom. The expressed sequence tags (ESTs) 
identified from the cDNA library belonged to 5 major superfamilies’ of snake 
venom proteins, namely, 3FTxs, serine protease inhibitors(SPIs), cysteine-rich 
secretory proteins (CRISPs), venom nerve growth factors (VNGFs), and 
PLA2s (Chatrath et al., 2011). Of all, 3FTxs constituted the largest family of 
toxins in the D. coronoides venom gland transcriptome. In this study we 
describe the characterization of a novel 3FTx (clone 13A), which was also 






 Novel features of drysdalin 
The clone 3FTx 13A, the longest (87 residues long) of all 3FTxs identified in 
the transcriptome of D. coronoides is termed drysdalin. Its protein sequence 
shows homology with long chain α-neurotoxins (LNTxs) (Figure 2.1). It has 
an extended C-terminus which is 24 residues long, compared to only 6-10 
residues in other LNTxs. The residues in the C-terminus have a propensity to 
form an α-helix in a modelled structure predicted by I-Tasser (Figure 2.2) 
(Roy et al., 2010a). The protein sequence of drysdalin lacks three functionally 
important residues which are replaced as Arg30, Leu34, and Ala37. The 
functionally important residues in α-cobratoxin at the homologous positions 
are Phe29, Arg33, and Arg36. The mutational studies on α-cobratoxin show 
that the mutations Phe29Leu/Trp/Ala, Arg33Glu, and Arg36Ala cause a 
decrease in binding to Torpedo acetylcholine receptor by a factor of 
12.4/1.29/3, 767, and 7.4, respectively (Antil et al., 1999), indicate the 
importance of these residues for binding to the Torpedo muscle receptor. 
These residues are also important for binding to the α7 receptor. The 
mutational studies on α-cobratoxin show that the mutations Phe29Ala, 
Arg33Glu, and Arg36Ala cause a decrease in binding to neuronal α7/5-HT3 
receptors by a factor of 74, 339, and 16, respectively (Antil-Delbeke et al., 
2000). The side chains of the residues Phe29 and Arg36 in α-cobratoxin form 
a cation-π interaction with Tyr185 in the receptor’s principal binding face, as 
seen in the crystal structure of Cbtx with Ls-AChBP (Bourne et al., 2005). 
Thus, we were interested to test the function of this unique protein, which 
lacks three functionally important residues and has a long C-tail. For the 
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characterization of drysdalin, we adopted recombinant expression in E.coli as 
the method to produce the protein. 
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Figure 2.1 Multiple sequence alignment of drysdalin 
Sequence alignment of drysdalin with homologous long chain neurotoxin sequences from other elapid species (A), cobratoxin and bungarotoxin 
(B). Toxin name, species and accession numbers (ACCN) are shown. At the end of each sequence, the number of amino acid residues is stated. 
The homology (sequence identity and similarity (%Id(Sm)) of each protein is compared with drysdalin. D.coronoides, Drysdalia coronoides; A. 
labialis, Austrelaps labialis; N. scutatus, Notechis scutatus; A. superbus Austrelaps superbus; B. candidus, Bungarus candidus; O. hannah, 
Ophiophagus hannah; P. rossignolii, Pseudechis rossignolii; N. kaouthia, Naja kaouthia; B. multicinctus, Bungarus multicinctus; α-δ-bgt-2, 
alpha-delta-bungarotoxin-2; Pr-LNTX, long chain neurotoxin from P. rossignolii; α-EPTX-Al2a, α-Elapitoxin Al2a ;Cbtx, α-Cobratoxin; Bgtx, 
α-Bungarotoxin. Residues highlighted in yellow, brown and green are specific to bind to muscle, neuronal α7, common functional residues to 
bind to both nAChRs. Residues highlighted in black are the conserved cysteine residues.
Name Organism ACCN        
A      
                                               Loop II  % Id(Sm) 
            Loop I                                                                            Loop III   
      
Drysdalin D. coronoides F8J2B3  
 
RKCYKTH--PYKSEPCASGENLCYTKTWCDFRCSQLGKAVELGCAATCPTTKPYEEVTCCSTDDCNRFPNWERPRPRPRGLLSSIMDHP 87  
α-EPTX-Al2a 
 
A. labialis B2BRQ6 
 
LRCYMG---PKTPRTCPPGENLCFTKTWCDPRCSLLGKLVKLGCAATCPIPKSYEDVTCCSTDNCNRFPKWERSRPRPRGLLSSIMDHP 86 73(79) 
Neurotoxin 
  



























FSCYKTP--DVKSEPCAPGENLCYTKTWCDRFCSIRGKVIELGCAATCPPAEPRKDITCCSTDNCNPHPAH------------------ 69 69(78) 








      
B      
                                                          Loop II   
                     Loop I                                                                                Loop III   
      




















      




Figure 2.2 Comparison of 3D drysdalin with classical long chain α-
neurotoxins 
Crystal structures of (A) α-cobratoxin (PDB 2CTX), (C) α-bungarotoxin (PDB 
1HC9) with the functionally conserved residues are shown in blue. (B) 
Modelled structure of drysdalin, with the 3 residues highlighted which  are 
different 
 
Recombinant protein expression in E. coli was adopted for protein production. 
The protein was refolded in solution and the in vivo, and ex vivo activities 
were tested on the mouse and chick neuromuscular junction, respectively.  
Whole animal testing give clues to the biological effect of venom and venom 
components (Vergara et al., 2014). For example, the intramuscular injection of 
the crude venom from the snake Naja haje in mice caused damage to the renal 
and hepatic tissues (Tohamy et al., 2014). The injection of recombinant 
inflamin in mice caused inflammation and writhing (Barnwal and Kini, 2013). 
 
The chick biventer cervicis muscle (CBCM) is a nerve-skeletal muscle 
preparation commonly used to evaluate the effect of a drug on neuromuscular 
junction (Crachi et al., 1999; Ginsborg and Warriner, 1960) . The biventer 
cervicis is innervated by nerves enclosed by the tendon attached to it. The chick 
muscle is multiply innervated, containing both fast and slow fibres. Stimulation of 
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the nerves via electrodes in contact with the tendon results in a contraction of the 
muscle generating a twitch response via the fast fibres. The slow fibres do not 
have a propagated action potential, but can be stimulated to give a slow 
contracture by addition of an exogenous agonist such as Ach/CCh or KCl, which 
causes direct muscle stimulation. Because of this advantage CBCM had been 
frequently used to assess the type of neurotoxicity and direct myotoxicity of the 
venom and toxins (Harvey et al., 1994). 
There are several ways by which venom and toxins can affect neuromuscular 
transmission. They can interact with the presynaptic membrane, interfering with 
the release of neurotransmitter molecules during an action potential, or they can 
bind to the postsynaptic nAChRs, thereby inhibiting the binding of ACh to these 
receptors. Additionally, the toxins can also exert their action by directly affecting 
the muscle, thereby producing myotoxicity. A presynaptic toxin abolishes the 
nerve evoked twitch response without affecting the response to the exogenous 
agonist ACh and/or CCh, but the response to the direct muscle stimulation elicited 
by KCl is restored (Rusmili et al., 2014). On the contrary, a postsynaptic toxin 
abolishes both the twitch response and the response to the exogenous agonists, but 
the response to the direct muscle stimulation by KCl is not affected (Nirthanan et 
al., 2003a). In the case of myotoxic effect, the toxin initiates a contracture of the 
muscle which has a slow onset and irreversible nature. The twitch response of the 
muscle to the nerve stimulation as well the response to the exogenous agonist is 
blocked irreversibly. In addition, the muscle then does not respond to the direct 





In this chapter, we describe the production of drysdalin, its function in vivo and its 





 Materials and methods 
 Bacterial strains and vectors 
The E. coli DH5α and vector pET-32a was purchased from Novagen (EMD 
chemicals Inc., Darmstadt, Germany). SHuffle competent E. coli expression 
cells were purchased from New England Biolabs (Ipswich, MA, USA). The 
proteins  with only N-terminal His-tag were expressed by cloning the synthetic 
gene in vector pET-M (modified pET-32a), devoid of thioredoxin tag (trx-tag) 
and S-tag (Appendix A.1).   
 Chemicals and other material 
Acetonitrile and trifluoroacetic acid (Merck KGaA, Darmstadt, Germany), 
Tris-HCL, NaCl from 1st Base Asia (Singapore), Luria Bertani- broth and 
agar (Q.BIOgene, Irvine, CA, USA).Most chemicals and drugs (acetylcholine, 
carbamylcholine chloride, α-bungarotoxin from Bungarus multicinctus) were 
purchased from Sigma (St. Louis, MO, USA). The other materials used were 
Precision Plus Protein™ Dual-colour standards (Hercules, CA, USA).  
 Reverse phase columns used for protein purification 
All reverse phase (RP) columns for High Performance Liquid 
Chromatography (HPLC) were purchased from Phenomenex (Torrance, CA, 
USA). They are 250 mm long silica-based Jupiter RP C18 columns with pore 
size 300 Å and particle size 5 μm. Their diameter varied from 4.6 mm for 




 Cloning of the synthetic gene into pET-M 
The 261 bp synthetic codon optimized gene (for expression in E.coli) in PUC-
57 was purchased from Genescript corporation (Piscataway, NJ, USA). The 
gene was cloned into pET-M as described by Dr Shifali Chatrath in her thesis. 
Briefly, the synthetic gene was amplified from PUC-57 with reverse and 
forward primers, RPop2: 5’ CAGCGGCCGCTCACGGATGATC 3’ and 
MF2: 5' GGGGATCCCGTAAATGCTATAAAACC 3', respectively. The 
amplified gene was cloned into pET-M within restriction sites for BamH1and 
NotI. 
 Transformation of plasmid for expression 
The recombinant plasmid harbouring the optimized gene was used to 
transform into SHuffle competent cells (expression hosts). Briefly, 1 µl (50 
ng/μl) of plasmid was mixed with competent cells and given heat shock at 
42°C for 90 s. After incubation at 37°C for 30-45 min with LB broth, the cells 
were plated (100 µl each plate) onto LB agar medium supplemented with 100 
µg/ml ampicillin (Amp). The plates were incubated overnight (12-16 h) at 
37°C. The transformation of the plasmid into the expression cells is 
considered as day 1 of protein expression. 
 Large scale protein expression 
Day 2: A single isolated colony from the LB agar plate of day 1 was 
inoculated into a 500 ml culture flask containing 100 ml of LB broth with 




Day 3: The overnight culture was inoculated into a 2.5 L culture flask with 1 L 
of fresh LB medium containing Amp (100 μg/μl). This culture flask was 
incubated at 37°C and 200 rpm until the culture reached an OD600 (optical 
density at 600 nm) of approximately 0.6-0.8. Glycerol stocks were made from 
this culture. In a 1.5 ml eppendorf tube, 80 µl of the culture and 20 µl of 80% 
sterilized glycerol are mixed and snap frozen in liquid nitrogen and kept at -
80°C until further use. 1 ml of culture was stored at 4°C as an uninduced 
control for SDS-PAGE analysis. The remaining culture was induced with the 
addition of IPTG stock concentration of 1 M to achieve a desired 
concentration. After induction, the culture was incubated at desired 
temperature (16°C or 37°C). For large scale production of protein (from 
inclusion bodies), SHuffle cells harbouring pET-M were induced with 1 mM 
IPTG and incubated at 37°C for 4 h. After incubation, another 1 ml was stored 
as induced control for SDS-PAGE analysis. The expression of recombinant 
protein in E. coli was analysed using 15% Tris-tricine gel electrophoresis 
(Appendix A.2). The induced cells were pelleted by centrifugation at 6000 
rpm for 30 min at 4°C. The cell pellets were stored at -80°C until further use. 
 Preparation of the inclusion bodies 
The induced cell pellets (1 L) were thawed on ice, and the cells were 
suspended in 30 ml lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 
mM EDTA and 0.1% Triton X-100). The solution was mixed by vortexing 
followed by ultrasonication (pulse frequency 1 s on and 1 s off cycles) for 15 
min for every 50 ml of sample. The sonication was done at 4°C, and the 
solution was kept on ice. When the solution changed from viscous to watery, it 
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indicated that lysis was nearing completion, so then it was centrifuged at 
18,000 rpm for 30 min at 4°C. The supernatant was stored to check for the 
presence of the desired protein. The above steps were repeated twice to obtain 
pure inclusion bodies. The pellet was kept at -20°C until further use. This 
method was adopted and modified from Sambrook and Russell (Sambrook and 
Russell, 2006).  
 Purification of reduced drysdalin by RP-HPLC 
The volume of denaturing buffer (50 mM Tris-HCl, 6 M GnHCl, pH 8.0) to 
dissolve the inclusion body pellet varied according to the yield of protein. On 
an average 30-40 ml denaturing buffer was used to dissolve the pellet from 1 l 
culture. For complete reduction of the disulphide bonds, DTT was used. The 
washed inclusion body solution, dissolved in denaturing buffer, was incubated 
with 50 mM DTT at 37°C for 1 h.  The reduced protein was filtered using 0.45 
μm filter, before purification on an RP-HPLC column attached to an AKTA 
purifier system (GE Healthcare Life Sciences, Piscataway, NJ, USA). The 
filtrate was injected onto a Jupiter C18 preparative column pre-equilibrated 
with buffer A (0.1% (v/v) Trifluoroacetic acid; TFA). Reduced drysdalin was 
eluted by RP-HPLC at a flow rate of 5 ml/min with a gradient of 35-45% of 
buffer B (80% (v/v) Acetonitrile, 0.1% (v/v) TFA) over 5 column volumes 
(CV). The elution was monitored at 215 and 280 nm. 
 Protein mass determination 
Fractions of interest were directly injected into an LCQ Fleet™ ion trap mass 
spectrometer (Thermo Fischer Scientific, Inc.) to determine the mass and 
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homogeneity of the protein. Electrospray ionization mass spectrum (ESI-MS) 
was acquired in positive ion mode with an orifice potential of 80 V. Nitrogen 
was used as curtain gas with a flow rate of 0.6 L/min and as nebulizer gas with 
a pressure setting of 100 psi. Full scan data were acquired over the ion range 
from 1000 to 2000 m/z with a step size of 0.1 Da. Analyte software 
(PerkinElmer Life Sciences, Wellesley, MA, USA) was used to analyze and 
deconvolute the raw mass data. Fractions showing the expected molecular 
mass were pooled and lyophilized. 
 Protein refolding 
The purified, reduced and lyophilized His-tagged protein was dissolved in the 
buffer (50 mM Tris-HCl with 3 M GnHCl, pH 8.0) to evaluate its 
concentration.  This was done using the molar extinction coefficient method 
on a NanoVue spectrophotometer (GE, etc.). The protein was incubated at 
37°C for 1 h with 50 mM DTT for complete reduction. The protein was 
diluted drop-wise into the refolding buffer (0.1 M Tris-HCl (pH 8.0), 0.5 M 
GnHCl, 1mM EDTA, 20% glycerol and GSH and GSSH at a molar ratio of 
1:1; 1 mM:1 mM) such that the total concentration of protein in the refolding 
mix was 0.05 mg/ml. This refolding mix was continuously stirred (50 rpm) 
gently for 3 days at 4°C. The refolding reaction was stopped by acidification 
with TFA (0.05-0.1% final TFA concentration) such that the pH of the 
solution was maintained at 3-5. The refolded protein was then purified on RP-
HPLC and eluted with a linear gradient of 32%-42% buffer B over 10 CV at 2 




 Measurement of Circular Dichroism (CD) spectra 
The secondary structure of the recombinant protein (10 μM in water) was 
determined by recording far-UV CD spectra (260-190 nm) on a Jasco J-810 
spectropolarimeter (Jasco Corporation, Tokyo, Japan) with a 2 mm path-
length cuvette. The cuvette chamber was continuously purged with nitrogen 
before and during the experiments to avoid absorption by oxygen. An average 
of three scans was taken to obtain a good signal to noise ratio. 
 Animals 
Swiss albino (SA) male mice (3 weeks, 20 ± 2 g) were used for the in vivo 
toxicity study. Animals were acquired from the National University of 
Singapore Laboratory Animal Centre and were acclimatized to the Animal 
Holding Unit surroundings for at least 3 days before the experiments. The 
mice were kept under standard conditions with food and water available ad 
libitum. They were housed four per cage in a light controlled room (12 h 
light/dark cycle, light on 0700 h) at 23°C and 60% relative humidity. For ex 
vivo experiments, 3 to 7-day-old domestic chicks (Gallus domesticus) 
(purchased from Chew’s Agricultural Farm, Singapore) were used. Chicks 
were received on the day of experimentation. All animal experiments were 
conducted according to the protocol (001/11) approved by the Institutional 




 In vivo toxicity in mice 
Refolded drysdalin was intraperitoneally (i.p.) injected in SA mice using 1⁄2 
in, 27-gauge needles (Becton-Dickinson, Franklin Lakes, NJ, USA) at 0.25 
and 3 mg/kg (n = 1). The doses were made up to a volume of 200 μl in 0.89% 
NaCl (physiological saline). The same volume of saline was injected i.p. to 
control animals (n = 1). The symptoms of envenomation were observed, and, 
in the event of death, the time was noted followed by a post mortem 
examination. 
 Chick Biventer Cervicis Muscle Preparation 
The Chick Biventer Cervicis Muscle (CBCM) are a pair of muscles located at the 
back of the animal’s neck and each muscle is associated with a tendon where the 
nerve supplying the muscle is located (Illustration). The CBCM contains two 
types of muscle fibres, fast-twitch muscle fibres and slow muscle fibres. The fast-
twitch muscle fibres are focally innervated and can be activated by electrical field 
stimulation (EFS) of the motor nerve inside the tendon, producing nerve-evoked 
twitch responses. The slow muscle fibres are multiply-innervated, and while they 
do not have a propagated action potential, they can be stimulated by the addition 
of exogenous agonists such as acetylcholine (ACh), carbamylcholine chloride 
(CCh) and potassium chloride (KCl) to give a sustained contracture (Toutant et 
al., 1981). The presence of these two types of muscle fibres, helps to distinguish 
between presynaptic and postsynaptic neurotoxins (Harvey Rowan et al., 1989; 
Geh et al., 1992; Harvey et al., 1994). For example, venoms and toxins can cause 
neurotransmission blockade via a pre-junctional mechanism by interfering with 
the release of neurotransmitters, or via a post-junctional mechanism by directly 
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inhibiting the nAChRs located on the postsynaptic motor-endplate. Hence, 
neurotoxin acting presynaptically would abolish nerve-evoked twitch responses 
without affecting the contractile responses to exogenously applied agonists. On 
the other hand, a neurotoxin acting postsynaptically will abolish both nerve-
evoked twitch responses as well as agonist-induced contractile responses in the 
muscle (Ginsborg and Warriner, 1960; Harvey, 1994). In addition, the CBCM can 
also be used to assess myotoxicity of venoms and toxins. Myotoxicity in the 
muscle is characterized by a slowly developing contraction of the muscle, 
inhibition of muscle response to exogenously applied KCl and reduction in twitch 
height in response to direct muscle stimulation (Hodgson et al., 2007). 
 
 
Figure 2.3 Schematic diagram of the ex-vivo organ bath assay CBCM. (A) Dissection of 
CBCM from the dorsal side of the chick. (B)CBCM mounted on the organ bath chamber (C) 
The transducer on top of organ bath transmits the electronic signals and the converted digital 
data can be seen on the computer screen. (D) A segment of trace showing a control 
experiment in which only buffer is added to the CBCM preparation. Figure 2.3 has been 




However, this will only provide pharmacological evidence of myotoxicity and 
histopathological examination of the muscle structure should be conducted to 
confirm the myotoxic effects of the venoms or toxins. The reversibility of 
neurotoxic activity of the venoms and toxins can also be assessed by repeated 
washing of the tissue preparations. Due to the robustness of this preparation and 
the ease of dissection, the CBCM is a useful preparation to screen for presynaptic 
and postsynaptic neurotoxins. 
Healthy chicks (1-3 days old) were euthanized by asphyxiation in an airtight 
chamber connected to a CO2 gas tank. A midline incision was made down the 
back of the neck, and the pair of biventer cervicis muscles, which lie on either 
side of the midline, were isolated. Each of the muscles is attached to a tissue 
holder with ring electrodes around the tendon and mounted in a 6 ml organ 
bath maintained at 37°C and containing Krebs buffer (118 mM NaCl, 4.8 mM 
KCl, 1.2 mM KH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3, 2.4 mM MgSO4, and 
11 mM D-(+) glucose); pH 7.4, continuously aerated with carbogen (5% CO2 
in O2).  
2.3.14.1 Recording the twitch responses 
Electrical field stimulation (EFS) was provided through platinum ring 
electrodes using a Grass stimulator S88 (Grass Instruments, West Warwick, 
RI, USA). Maximal twitch responses of the muscle were elicited indirectly via 
stimulation of the motor nerve by applying an electrical field of 7–10 V 
potential difference at a frequency of 0.2 Hz in supramaximal rectangular 
pulses of 0.1 ms duration. For direct muscle stimulation, the electrodes were 
lowered from the tendon towards the belly of the muscle and twitch response 
was evoked by electric field stimulation (0.2 Hz, 1 ms, 20-30 V). The 
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magnitude of the contractile response was measured in gram (g). The resting 
tension of the tissues was maintained at 1-2 g and the preparations were 
allowed to equilibrate for 30-45 min.  The data was continuously recorded on 
a PowerLab/Chart 5 data acquisition system via a force displacement 
transducer (Model MLT0201) (AD Instruments, Bella Vista, NSW, and 
Australia). 
2.3.14.2 Ex-vivo toxicity of drysdalin 
The effect of drysdalin on the twitch responses of the CBCM to nerve or direct 
muscle stimulation is examined. Each preparation was exposed to one 
concentration of the toxin. The effects of drysdalin on the responses of the 
CBCM to exogenous ACh, CCh or KCl were investigated immediately after 
complete blockade of nerve-evoked twitch responses was established. In 
separate experiments, the reversibility of the inhibitory effect of the toxins on 
the twitches was assessed by thoroughly washing the muscle preparation with 
Krebs solution, at 30 min intervals (3 cycles of 30 s on-30 s off pulse) over a 
period of 120 min after at least 80% of the blockade had taken place. The 
neuromuscular blockade produced by drysdalin was expressed as a percentage 
of the original twitch height before exposure to the toxin. Dose response 
curves of drysdalin (10 nM-0.5 μM; n = 3) after 15 and 30 min of exposure to 





 Results and discussion 
 Expression and purification of drysdalin 
SHuffle cells (constitutively expressing a chromosomal copy of the disulphide 
bond isomerase DsbC) harbouring pET-M/drysdalin construct was used for 
the protein expression. The expression conditions were optimized by changing 
different parameters like temperature/incubation time after induction (16 
°C/20 h, 37 °C/4 h), IPTG concentration (0.1, 0.5, 1 mM). The optimized 
conditions for expression are induction with 1 mM IPTG followed by 
incubation at 37°C for 4 h. Analysis of induced protein in 15% Tris-Tricine 
PAGE showed the expression of a protein of apparent molecular weight(MW) 
of ~15 kDa (Figure 2.4). The calculated MW of His-tagged drysdalin is 11.7 
kDa, where ~2 kDa is contributed by His-tag and the thrombin cleavage site. 
The apparent slow mobility could be attributed to the several basic residues 
present in the protein. We observed that the protein was mostly present in the 
insoluble fraction and hence further purification was done under denaturing 
conditions (Figure 2.4).  
Initially the His-tagged drysdalin was purified by Ni-NTA (Nickel-
Nitrilotriacetic acid) affinity column purification. Due to incomplete binding 
of the protein to the affinity column (which could not be improved by the use 
of new Ni-NTA beads or increasing the beads quantity), loss in the washes, 
and Ni+2 metal-ion induced oxidation of the protein, we discontinued 
purification by this method (data not shown). Thus, we adopted a method for 
the inclusion body preparation wherein the cell pellet was washed three times 
with buffer containing 1% Triton X-100. In this way we recovered 90-95% of 
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the expressed protein from the cell pellet. The decision to retain the His-tag, 
even though it was not used for purification, was because the tag could be 
used, in the future studies, for pull-down assays for receptor-protein 
interaction. 
The washed cell pellet (pure inclusion bodies) is completely reduced, 
denatured and purified by RP-HPLC (Figure 2.5A). The ESI-MS shows six 
peaks of mass/charge (m/z) ratios ranging from +6 to +11 charges (Figure 
2.5B). The mass was estimated to be 11731.63 ± 0.56 Da which matches the 
calculated mass of 11732 Da. The HPLC profile and the ESI-MS confirm the 
homogeneity of the reduced protein. 
 
Figure 2.4 Tris-Tricine SDS-PAGE (15%) analysis of His-tagged 
drysdalin 
Samples of the His-tagged drysdalin expressed in pET-M was resolved on 
15% Tris-Tricine gel stained with Coomassie brilliant Blue-R 250 and 
compared to pre-stained protein ladder (1st Base). A thick band of the desired 
protein (~15kDa) in the induced samples (I) can be seen as compared to the 
uninduced sample. Bracketed are the IPTG concentrations and incubation 
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temperature, respectively. W1 and W2 are the washes with 1% Triton X-100 








Figure 2.5 Purification of drysdalin 
(A) RP-HPLC of reduced drysdalin from the inclusion bodies of SHuffle cells. 
A Jupiter C18 (5 μ, 300 Å, 4.5 x 21.2 mm) preparative column was 
equilibrated with 0.1% (v/v) TFA. Drysdalin was eluted from the column at a 
flow rate of 5 ml/min with gradient of 35-45% buffer B (80% ACN in 0.1% 
TFA) over 5 CV. The dotted line indicates the gradient of buffer B. The 
downward arrow indicates the fraction containing drysdalin. (B) ESI-MS 
profile of the RP-HPLC fraction containing drysdalin. The spectrum shows a 
series of multiply charged ions, corresponding to a single, homogenous protein 
with a molecular mass of 11731.63 ± 0.56 Da. Inset, reconstructed mass 




 Refolding of drysdalin 
The freeze-dried, reduced protein is used for refolding by the dilution method. 
The refolded protein, when run on a semi-preparative column, eluted as a 
single major peak followed by many small peaks (Figure 2.6A). The major 
peak (black arrow) is further purified to homogeneity using an analytical 
column (Figure 2.6B). The ESI-MS shows six peaks ranging from +6 to +11 
in charge (Figure 2.6C). The mass was estimated to be 11721.87 ± 0.63 Da 
which matches the calculated mass of 11722 Da. The loss of 10 Da compared 
to reduced protein suggests that all cysteine residues have been oxidized to 
form 5 disulphide bonds. The HPLC profile and the ESI-MS confirm the 
homogeneity of the refolded protein.  
Ensuring the homogeneity of refolded protein is extremely important. Since 
drysdalin has 10 cysteine residues, the protein can fold in many different 
conformations. For the functional characterization the homogeneity ensures 
the attribution of the function to only one fold.  
Refolding 3FTxs poses a unique problem, because there are 8-10 cysteine 
residues forming 4-5 disulphide bonds in a small protein. Hence, during 
attempts to improve the yield of refolded drysdalin, certain observations were 
made. Additives like PEG 3000, 0.4 M L-arginine, 20% ACN did not improve 
the yield of drysdalin. Instead they stabilized the intermediates (proteins with 
different folds during shuffling), yielding a non-homogenous mixture of 
protein (data not shown). Stopping the refolding (shuffling of disulphide 
bonds under redox conditions, basic pH) by acidification with TFA is an 
extremely important step. The pH was changed from basic 8.0 to acidic 2-3 by 
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the addition of TFA which stops the shuffling reaction and stabilizes the 








Figure 2.6 Purification of refolded drysdalin 
The RP-HPLC profile of drysdalin from the refolding buffer. (A) A Jupiter 
C18 (5 μ, 300 Å, 4.5 x 10 mm) semi-preparative column was equilibrated with 
0.1% (v/v) TFA. Refolded drysdalin was eluted from the column at a flow rate 
of 2 ml/min with a gradient of 32-42% buffer B (80% ACN in 0.1% TFA) 
over 10 CV. (B) Jupiter  C18 (5 μ, 300 Å, 4.5 x 4.6 mm) analytical column 
was equilibrated with 0.1% (v/v) TFA. Refolded drysdalin was eluted from the 
column at a flow rate of 1 ml/min with gradient of 32-42% buffer B over 20 
CV. The dotted line indicates the gradient of the buffer B. The downward 
arrow indicates fraction containing refolded drysdalin. (B) ESI-MS profile of 
the RP-HPLC fraction containing refolded drysdalin. The spectrum shows a 
series of multiply charged ions, corresponding to a single, homogenous protein 
with a molecular mass of 11721.87 ± 0.63 Da. Inset, reconstructed mass 
spectrum of drysdalin; cps = counts/s; amu = atomic mass unit. 
 
 Secondary structure of drysdalin 
The CD spectrum of drysdalin shows a minimum at 206-209 nm. This 
indicates that drysdalin contains β-sheeted structures, like other 3FTxs 
(Pawlak et al., 2009; Roy et al., 2010b). As expected, long-chain α-
neurotoxins, α-bungarotoxin (Bgtx) and α-cobratoxin (Cbtx) show a maximum 
around 230 nm and a minimum around 210 nm, indicating a predominant β-
sheeted structure. No helical conformation could be observed from the CD 
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spectrum. This could indicate either the absence of α-helix at the C-terminal or 
that the signal for α-helix might have been masked by the signal from the high 
content of β-sheets. In order to elucidate the 3D structure of drysdalin 
crystallization studies are being carried out in the lab. 
 
Figure 2.7 Far UV-CD spectrum of drysdalin 
Drysdalin shows a minimum around 206-209 nm, indicating a β-sheeted 
secondary structure in the protein. Known long-chain α-neurotoxins, α-
bungarotoxin (Bgtx) and α-cobratoxin (Cbtx) are shown for comparison.  
 
 In vivo toxicity in mice 
Mice injected with 0.25 or 3 mg/kg of drysdalin showed the typical signs of 
peripheral neurotoxicity, such as paralysis of the hind limbs and laboured 
breathing, and finally died (at 3 mg/kg), presumably due to respiratory 
paralysis (Laothong and Sitprija, 2001; Warrell et al., 1983b). At the low 
concentration of 0.25 mg/kg, the mice survived when observed after 24 h of 
toxin injection, but with impaired locomotion. On post-mortem, no gross 
change in the internal organs was observed. 
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 Ex vivo toxicity in Chick Biventer Cervicis Muscle preparation 
Drysdalin produced a blockade of the nerve evoked twitch responses of 
CBCM (Figure 2.8). The contractile response to exogenous agonists (ACh 
and CCh) was completely inhibited by drysdalin, whereas the response to 
exogenous KCl and twitches evoked by direct muscle stimulation were not 
inhibited.  This indicates a post-synaptic neuromuscular blockade and an 
absence of direct myotoxicity. The effects of different concentrations of 
drysdalin were examined on CBCM. It was observed that drysdalin produces a 
dose-dependent effect. A dose-response curve was plotted for % blockage at 
15 and 30 min and IC50 was determined to be 68.9 ± 8.6 nM and 38.7 ± 5.7 
nM (Figure 2.9). Thus, drysdalin shows only 3-fold less activity than the 







Figure 2.8 Effect of drysdalin on the chick biventer cervicis muscle 
preparation (CBCM) 
A segment of trace showing the effect of drysdalin (0.3 μM) on the twitch 
response of CBCM. Twitch response of the muscle was evoked by electrical 
field stimulation (EFS, indicated by the black bar) and by exogenous agonists, 
acetylcholine (ACh; 300 μM), carbachol (CCh; 10 μM) and potassium 
chloride (KCl; 30 mM). The vertical bar represents the magnitude of twitch 






Figure 2.9 Dose-response curve of drysdalin on CBCM 
Dose-dependent inhibition of contractile responses by drysdalin (A) 15 min 
and (B) 30 min after the addition of toxin to CBCM. Blockage is calculated as 
a percentage of the control twitch responses to supramaximal nerve 
stimulation before addition of protein. Each data point is the mean ± SE of two 
to four experiments. 
 
 Reversibility of drysdalin  
Drysdalin produced an irreversible blockage of the nerve-evoked twitch 
responses in CBCM with no signs of reversal of binding even after washing 
for 120 min (Figure 2.10). It has been suggested that the reversibility of 
binding of α-neurotoxins may be associated with a specific area or set of 
residues in the toxin that interact with the receptor. For instance, Asp31 is 
absent in the reversible toxins such as candoxin (Nirthanan et al., 2003a), 
CM10, CM12 and LSIII (Harvey et al., 1984). Asp31 is shown to form a 
hydrogen bond with the Tyr109 of the mouse α1 subunit thereby anchoring the 
toxin into the ligand binding pocket (Dellisanti et al., 2007). Thus it is possible 




Figure 2.10 Irreversibility of the nerve-evoked twitch response blockage 
by drysdalin in CBCM 
A segment of trace showing the irreversible block of nerve-evoked twitch 
responses by drysdalin (0.5 μM) in CBCM after washing for 120 min; (point 
of beginning of wash; W).  Contractions produced by exogenous KCl (30 




Drysdalin was expressed recombinantly in the inclusion bodies of E. coli 
SHuffle cells, with a 20 mg/L yield of reduced protein. It was successfully 
refolded in a redox buffer and purified to homogeneity by RP-HPLC. The 
mass of the refolded protein was confirmed by ESI-MS and the CD spectrum 
of drysdalin showed a characteristic minimum between 210-215 nm, 
indicating it is a β-sheeted structure. 
Mice, when injected with refolded drysdalin, show peripheral neurotoxic 
symptoms. Drysdalin causes post-synaptic irreversible blockage of the twitch 
responses on chick biventer cervicis muscle preparation with IC50 only 3-fold 
less when compared to α-bungarotoxin. This activity is in contrast to the lack 
of functionally important residues at the homologous position in drysdalin. 
This indicates that either a different set of residues in drysdalin are functional 
or drysdalin binds to a different site on the receptor. Also, the long C-terminal 
tail might play a role by stabilizing drysdalin structure or a functional role by 
interacting with nAChRs. This could be studied by determining the three –
dimensional structure of drysdalin by crystallization studies. 
It is known that long chain α-neurotoxins bind to both muscle and neuronal 
receptors (Nirthanan and Gwee, 2004). Thus receptor binding studies of long 
chain α-neurotoxin drysdalin was carried out on different receptors as 















We established that drysdalin shows neurotoxic effects in mice and chick 
biventer cervicis muscle preparation. Drysdalin shows sequence similarity to 
long-chain α-neurotoxins (Figure 2.2) which are potent competitive 
antagonists of nicotinic acetylcholine receptors (nAChRs). Both short-chain 
and long-chain α-neurotoxins interact with muscle nAChRs, whereas only 
long-chain α-neurotoxin bind to neuronal homopentameric α7, α8, and α9 
nicotinic receptors and heteromeric receptors composed of α7-α10 subunits. 
The ability of toxins to bind to various nAChR subtypes can be studied by 
two-voltage electrode clamp (TEVC) technique.  
It is a conventional electrophysiological technique used to artificially control 
the membrane potential (Vm) of large cells in order to study the properties of 
electrogenic membrane proteins, especially ion channels. It makes use of two 
intracellular electrodes, a voltage electrode as Vm sensor and a current 
electrode to adjust the Vm.  This allows for setting the membrane potential at 
desired values so the membrane current can be recorded for analysis of ion 
channel activities. TEVC has been widely used in combination with 
exogenous mRNA expression in Xenopus oocytes for ion channel recording 
(Guan et al., 2013). Xenopus oocytes are large in size (> 1 mm in diameter), 
which allows for easy manipulation. The low expression of endogenous 
channels and receptors on the membrane makes it a widely used system to 
study the structure and function of exogenous ion channels. The unique 
selectivity profiles of human neuronal nAChRs (hα2β2, hα2β4, hα3β2, hα3β4, 
58 
 
hα4β2, hα4β4 and hα7) to nicotinic agonists and antagonists constitutes a 
valuable tool for studying the subtype selectivity of toxins (Chavez-Noriega et 
al., 1997).  
Xenopus oocytes endogenously express a quite large Ca2+-dependent Cl- 
current, ICl- [Ca2+] (Hartzell et al., 2005). With maximal stimulation ICl- [Ca2+] 
can reach several tens of μA of current. Thus activation of Ca2+-permeable 
channels leads to an influx of Ca2+ that inevitably activates this endogenous 
current and confounds measurements. It is also practically impossible to 
manipulate the intracellular Ca2+ concentration in order to study its effect on 
expressed channels. This is a general problem with the expression of Ca2+ 
permeable channels or channels that depend on intracellular Ca2+. Thus to 
measure the effect of drysdalin on the intracellular Ca2+ influx we used HEK 
(Human embryonic kidney) cell lines with a Ca2+ sensing reporter.  
To further understand drysdalin mode of function, its binding to acetylcholine 




 Materials and methods 
 Reagents and kits 
The antibiotics gentamycin, penicillin, streptomycin were obtained from 
Sigma-Aldrich. The reagents required for the cell culture like DMEM was 
purchased from Mediatech, Manassas, VA; FBS  from Gemini Bio-Products, 
West Sacramento, CA; glutamine from Invitrogen, Carlsbad, CA. The TC-
treated 96-well plates were purchased from E&K, Greiner Campbell, CA. 
PNU-120596 was purchased from Tocris, Ellisville, MO. 
 Electrophysiological characterization of drysdalin 
Two-electrode voltage-clamp (TEVC) experiments were done using Xenopus 
oocytes to observe the effect of drysdalin on mouse muscle (αβεδ) and human 
α7 nAChRs. The electrophysiological studies described below were carried 
out in the collaboration with Professor David Adams, RMIT University, and 
Bundoora campus. 
3.2.2.1 cRNA preparation 
Plasmid DNAs encoding mouse α1, β1,ε and δ subunits and human α7 nAChR 
subunits were linearized with appropriate restriction enzymes, and cRNA was 
synthesised in vitro using a SP6 or T7 in vitro transcription kit (mMessage 




3.2.2.2 Oocyte preparation and microinjection 
Stage V-VI oocytes were obtained from Xenopus laevis, defolliculated with 
1.5 mg/ml collagenase (Type I, Sigma) in OR-2 solution (82.5 mM NaCl, 2 
mM KCl, 1 mM MgCl2 and 5 mM HEPES at pH 7.4). Oocytes were injected 
with 5 ng of cRNA using glass pipettes pulled from glass capillaries (3-000-
203 GX, Drummond Scientific Co.). Oocytes were incubated at 18ºC in sterile 
ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 5 
mM HEPES at pH 7.4) supplemented with 5% FBS, 50 mg/l gentamycin and 
100 μg/units/ml penicillin-streptomycin. Electrophysiological recordings were 
carried out 2–7 days after microinjection. 
3.2.2.3 Electrophysiological recordings and data analysis 
Two-electrode voltage clamp recordings from oocytes were carried out at 
room temperature using a GeneClamp 500B amplifier (Molecular devices 
Corp., Sunnyvale, CA) at a holding potential -80 mV. Voltage-recording and 
current-injecting electrodes were pulled from borosilicate glass (GC150T-7.5, 
Harvard Apparatus Ltd.) and had resistances of 0.3–1 mΩ when filled with 
3 M KCl.  
A continuous push/pull syringe pump perfusion system was used to perfuse 
oocytes with ND96 at a rate of 2 ml/min. nAChR–mediated currents were 
evoked by application of acetylcholine (ACh) at a rate of 2 ml/min via the 
perfusion system. Washout periods of 180–240 s between applications of ACh 
were used. ACh EC50 concentration (1 μM for mouse αβεδ-, 200 μM for 
human α7-nAChR) was applied to the oocytes.  Oocytes were incubated with 
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the toxin for 4 min before ACh was co-applied. ACh and the toxin contained 
0.1% bovine serum albumin. Peak ACh-evoked current amplitude was 
recorded before and after toxin incubation using pClamp 9 software 
(Molecular Devices Corp.).  
The concentration-response curves were obtained by plotting averaged relative 
peak current amplitude values (I/Icontrol) against toxin concentration and fitting 
the resulting data by the hill equation I = where Icontrol ([TX] n / (IC50n + [TX] 
n)), is the maximum peak current amplitude, [TX] the toxin concentration, on 
the Hill coefficient, and IC50 the agonist concentration that produces 50% of 
the maximum response.  
 
 
Figure 3.1 Schematic representations of the TEVC experiments 
This illustration shows the flow of the two-electrode voltage clamping experiments which 
includes mRNA preparation, micro-injection and expression of nAChRs on Xenopus oocytes  
 
Flex Assays with CNiFER Cells 
The flex assay described below were carried out in collaboration with 
Professor Palmer Taylor, Skaggs School of Pharmacy and Pharmaceutical 
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Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, 
California 92093, United States of America. 
Stable cell-based neurotransmitter fluorescently engineered reporter (CNiFER) 
cell lines expressing human α7-nAChRs with RIC3 (HEKtsA201 cells) were 
prepared as described previously (Yamauchi et al., 2011). The CNiFER cell 
line contained the genetically encoded Ca2+ sensor TN-XXL (Mank et al., 
2008), for measurements of Ca2+ flux through the pLGICs. Cells were cultured 
in 10 cm plates with DMEM supplemented with 10% FBS and 1% Glutamine 
and incubated at 37°C with 10% CO2. Cells were selected at 70% confluency 
and plated one day before (100 μl volumes per well) into black, transparent 
flat-bottom, TC treated 96-well plates and incubated at 37°C and 10% CO2. 
Next day the media was replaced with 100 μl of artificial cerebral spinal fluid 
(aCSF) [containing 121 mM NaCl, 2.4 mM Ca2+, 1.3 mM Mg2+, 5 mM KCl, 
26 mM NaHCO3, 1.2 mM Na2HPO4, 10 mM glucose, 5 mM HEPES, pH 7.4, 
Appendix A.3], including the antagonists. For all assays performed on α7-
nAChR CNiFERs 10 μM of the positive allosteric modulator (PAM), PNU-
120596 (N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea), 
was prepared in aCSF. Antagonists, at 1.5 times the final desired 
concentration, were prepared in aCSF with PNU. Plates were incubated for at 
least 30 min at 37°C and 10% CO2. Following incubation, plates were 
removed and placed into the Molecular Devices FlexStation III instrument and 
run at 37°C. Injection rates varied between 27–48 ml/s, and 50 μl of the 
epibatidine prepared at 3X final concentration in the aCSF solution was 
injected after 30 s of baseline measurement. Epibatidine at a final 
concentration of 0.1 μM is used. Reads of both donor eCFP (485 nm) and 
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acceptor Citrine cp174 (527 nm) emission with eCFP excitation (436 nm) 
were made at 3.52 s intervals. 
3.2.2.4 Data analysis for the flex assay 
FRET ratios of the two wavelengths were plotted and the peak height or initial 
rate of ion flux for the well was determined using SoftMax Pro 5.2 (Molecular 
Devices). All wells were replicated (four times) in the same plate. Mean peak 
FRET ratios calculated from replicates were exported, normalized to the 
minimum (no epibatidine) and maximum (0.1 μM epibatidine) responses and 
plotted against antagonist concentrations using Graphpad Prism 5 (Carlsbad, 
CA). A sigmoidal dose-response (variable slope) regression of the mean peak 
FRET ratios was fit to generate a dose-response curve and obtain an EC50 
value of the antagonist. 
 
 Radioligand binding assay with acetylcholine binding proteins 
The interaction studies of drysdalin with acetylcholine binding protein 
(AChBP), described below were carried out in collaboration with Professor 
Palmer Taylor, Skaggs School of Pharmacy and Pharmaceutical Sciences, 
University of California, San Diego, 9500 Gilman Drive, La Jolla, California 
92093, United States of America.  
An anti-mouse scintillation proximity assay (SPA, Amersham Biosciences, 
and Piscataway, NJ, USA) was adapted to determine the apparent Kd values 
for the protein (Hibbs et al., 2004). Three soluble acetylcholine-binding 
proteins (AChBP) were used in this study. AChBP from the freshwater snail 
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Lymnaea stagnalis (Ls), the marine species Aplysia californica (Ac) along 
with one mutant of Ac binding protein were used. All the binding proteins 
were recombinantly expressed in HEK cells and purified in Professor Taylor’s 
lab.  
Briefly, 12 μl mixture containing AChBP (final concentration ~500 pM 
binding sites for Ls and AcY55W; ~1 nM binding sites for Ac), 
polyvinyltoluene anti-mouse SPA scintillation beads (0.17mg/ml, final 
concentration) and monoclonal anti-FLAG M2 antibody from mouse (1:8000 
dilution, final concentration), is combined with 12 μl of test ligand and 
incubated for 15 min before the addition of 24 μl [3H] epibatidine (final 
concentration of 5 nM for Ls and AcY55W, 20 nM for Ac). The final mixtures 
were allowed to equilibrate for another 1 h before measuring relative 
radioactivity in the Beckman LS 6500 liquid scintillation counter.  
 
Nonspecific binding is determined by adding saturating concentration (10 μM) 
of methyllycaconitine(MLA) to an identical set of wells. Total binding is 
determined in the absence of competing ligand. All the raw counts are then 
normalized for the total binding and the nonspecific binding for analysis. 
Since this is a competition assay, the greatest inhibition reflects the greatest 
potency. Nicotine is used as an internal standard ligand to verify proper 
functioning of the assay. All assays are performed in 0.1M NaPO4 buffer, 
0.1% BSA, pH 7.0 at room temperature. 
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3.2.3.1 Quick Screen 
The quick screen experiments are performed to determine the relative binding 
affinities at a single, 10 μM final concentrations in the above described assay. 
At least two independent experiments with duplicate measurements are 
performed. 
3.2.3.2 Kd assays 
Kd assays are conducted in a similar manner except that ligand concentrations 
are varying in the wide range. The data obtained are normalized and the Kd 
value will be calculated from the observed EC50 value using GraphPad Prism 5 
(GraphPad Software, San Diego, CA, USA, www.graphpad.com). A minimum 
of three independent experiments with duplicate measurements were 




 Results and discussion 
 Effect of drysdalin on mouse αβεδ-nAChRs expressed on Xenopus 
oocytes 
Xenopus oocytes expressing mouse muscle nAChRs were challenged with 
various concentrations of drysdalin. At a concentration of 300 nM, drysdalin 
completely inhibited the ACh-induced currents produced by the mouse αβεδ-
nAChRs (Figure 3.2A). Drysdalin was able to inhibit the ACh-induced 
currents in a dose-dependent manner over the range of 1-300 nM. The 
inhibition dose-response curve allows a determination of the IC50 of 16.9 nM 
(Figure 3.2B). The Hill coefficient was determined to be 1.3, indicating 
similar affinities to the two AChR-binding sites. The classical long-chain α-
neurotoxins α-bungarotoxin and α-cobratoxin, which bind to muscle nAChR, 
were also tested. The IC50 values were determined to be 13.96 nM and 1.33 









Figure 3.2 Effect of drysdalin on mouse αβεδ-nAChRs expressed on 
Xenopus oocytes 
(A) Representative whole-cell currents from Xenopus oocytes expressing 
mouse αβεδ-nAChR elicited by 1 μM ACh and subsequent application of 1 
μM ACh with increasing concentrations of drysdalin. (B) Inhibition curves of 
the normalized data, IC50 and Hill coefficient (nH) of drysdalin were 
determined to be 16.9 nM and 1.3, respectively. α-Bungarotoxin (Bgtx) and α-
cobratoxin (Cbtx) are shown for comparison. Each data point is the mean ± 




 Effect of drysdalin on human α7-nAChRs expressed on Xenopus 
oocytes 
Xenopus oocytes expressing human α7-nAChRs were challenged with various 
concentrations of drysdalin. At a concentration of 300 nM drysdalin 
completely inhibited the ACh-induced currents produced by the human α7-
nAChRs (Figure 3.3A). Drysdalin inhibited ACh-induced currents in a dose-
dependent manner over a range of 0.3-300 nM. An inhibition dose-response 
curve was plotted and the IC50 was determined to be 10 nM (Figure 3.3B). 
The Hill coefficient was determined to be ~2, indicating that drysdalin shows 
positive cooperativity towards α7-nAChRs. In the same experimental set-up 
IC50 of α-bungarotoxin and α-cobratoxin was determined to be 5 nM and 1.8 




Figure 3.3 Effect of drysdalin on human α7-nAChRs expressed on 
Xenopus oocytes 
(A) Representative whole-cell currents from Xenopus oocytes expressing 
human α7-nAChR elicited by 200 μM ACh and subsequent application of 200 
μM ACh with increasing concentration of drysdalin. (B) Inhibition curves of 
the normalized data, IC50 and Hill coefficient (nH) are determined to be 9.98 
nM and 1.9, respectively. α-Bungarotoxin (Bgtx), α-cobratoxin (Cbtx) is 
shown for comparison. Each data point is the mean ± S.E of minimum of 5 





 nAChR subtype specificity of drysdalin 
Electrophysiology experiments were conducted on muscle and α7 receptors to 
find to which receptors drysdalin binds. We chose these two receptors because 
long chain α-neurotoxins are known to bind both muscle and neuronal α7-
nAChRs (Antil-Delbeke et al., 2000). Hence, to determine if drysdalin shows 
any difference in the affinities to the receptors or subtype selectivity, we 
conducted TEVC experiment.  
Drysdalin showed a dose-dependent inhibition for both mouse muscle and 
human α7-nAChRs, with IC50s of 16.9 nM and 9.98 nM, respectively. This is 
interesting because of the lack of functionally important residues in drysdalin.  
Previous mutation studies reveal that Cbtx “commonly” uses Trp25, Asp27, 
Phe29, Arg33, Arg36 and Phe65 to bind to both muscle nAChR and neuronal 
nAChR (Antil-Delbeke et al., 2000). The common functional residues are 
assisted by Ala28, Cys26–Cys30, and Lys35, for binding to α7-AChR, and by 
Lys23 and Lys49, which recognize muscular-AChR.  
3.3.3.1 Binding to mouse αβεδ-nAChRs  
The mutations of the residues Phe29Leu, Arg33Gln, and Arg36Ala in Cbtx 
have shown to decrease its binding to Torpedo muscle receptor by 12.4, 767, 
and 7.4 times, respectively, highlighting the importance of these 3 functional 
residues in Cbtx (Antil et al., 1999). In spite of changes in residues Arg30, 
Leu34, and Ala37 (homologous to mutations in Cbtx), drysdalin shows only 
12.7-fold less affinity compared to Cbtx (IC50 = 1.33nM). This could be 
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because drysdalin has other residues (Trp26, Asp28, and Phe65) in loop II and 
III in addition to Lys23 and Lys50, which are shown to be important in 
binding to the muscle receptor (as seen from the Cbtx residues at homologous 
positions). Is it also possible that residues in drysdalin (Arg30, Leu34 and 
Ala37) are contributing of its binding to the muscle nAChR. 
3.3.3.2 Binding to human α7-nAChR 
Drysdalin shows only 5-fold less affinity (IC50 = 9.98 nM) to human α7 
nAChR when compared to Cbtx (IC50 = 1.8 nM). This is interesting because 
drysdalin lacks the functionally important residues of Cbtx. The mutation of 
residues Phe29Ala, Arg33Gln and Arg36Ala in Cbtx resulted in a 74-, 339-, 
and 16- fold reduction in affinity to α7/5-HT3 receptor (Antil-Delbeke et al., 
2000) Also the mutation Ala28Gly in Cbtx resulted in 5.4-fold decrease in 
affinity to α7/5-HT3 receptor.  
Inspite of change in these residues (Phe29,Arg30, Leu34, Ala37) drysdalin 
shows only 5-fold less affinity compared to Cbtx (IC50 1.8nM). This could 
probably be because drysdalin has other residues Trp26, Asp28 and Phe65 in 
the loop II and III  in addition to Cys27-Cys31, Lys36 which are shown to be 
important in binding to α7 receptor (As seen from the Cbtx residues at the 
homologous positions). Is it also possible that residues in drysdalin (Arg30, 
Leu34, Ala37) are contributing of its binding to the α7-nAChR. 
 Effect of drysdalin α7-nAChR CNiFERs 
Ca2+ sensing HEK cells expressing human α7-nAChR were challenged with 
various concentrations of drysdalin. Drysdalin at 100 nM completely blocked 
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the epibatidine responses from the α7-nAChR CNiFERs (Figure 3.4). 
Drysdalin (0.3- 100 nM) showed a dose-dependent blockage of the 
epibatidine-elicited responses in the α7-nAChR CNiFERs. An inhibition dose-
response curve gave an EC50 value of 8.5 nM. Bgtx and Cbtx EC50s were 
determined to be 2 nM and 7.4 nM, respectively. MLA is used as a positive 
control, a known antagonist to human α7-nAChRs, also shows dose-dependent 
inhibition. In this assay too, drysdalin shows only 4-fold less activity when 
compared to Bgtx and similar affinity compared to Cbtx. This is in contrast to 
the lack of the functionally important residues in drysdalin. This suggests that 
drysdalin uses different set of residues in its sequence to interact with the 
human α7-nAChRs. 
 
Figure 3.4 Effect of drysdalin α7-nAChR CNiFERs 
Competitive blockage of the epibatidine elicited responses on α7-nAChR 
CNiFERs by drysdalin is plotted as a normalized response. The EC50 value 
was determined to be 8.5 nM. α-Bungarotoxin (Bgtx) and α-cobratoxin (Cbtx) 
shown for comparison. Each data point is the mean ± S.E of minimum of 3 





 Interaction of drysdalin with AChBPs 
Drysdalin was screened for its ability to compete or interfere with the binding 
of [3H] epibatidine to the 3 AChBPs (Ls, Ac, AcY55W) as measured by a 
scintillation proximity assay (Figure 3.5). In the quick screen, drysdalin (10 
μM) shows significant interference (fraction of bound [3H] epibatidine <0.5) 
for the binding of [3H] epibatidine to all the 3 binding proteins, suggesting that 
drysdalin may compete with [3H] epibatidine for the same binding site. α- 
Bungarotoxin and α- cobratoxin, well-known long-chain α-neurotoxins, also 
show significant interference for the binding of [3H] epibatidine to Ls-, Ac-
AChBP but not towards Ac mutant. Nicotine, a known ligand for AChBPs, is 









Figure 3.5 Interaction of drysdalin with acetylcholine binding proteins 
and its mutant 
Competitive radioligand binding assay of drysdalin vs. acetylcholine binding 
proteins (Ls: Lymnaea stagnalis; Ac: Aplysia californica and AcY55W: 
Aplysia californica mutant). The concentration of drysdalin, α-bungarotoxin 
(Bgtx) and α-cobratoxin (Cbtx) used was 10 μM. Nicotine (10 μM) was used 
as positive control. The radioligand used is [3H] epibatidine. Results are 
expressed as fraction of bound [3H] epibatidine. 
 
 Dissociation constants of drysdalin binding to the AChBPs 
A scintillation proximity assay was employed to measure the ligand binding. 
Varying concentrations of drysdalin (0.3 nM- 10 μM, n=3) was incubated with 
the AChBP and the competing ligand [3H] epibatidine. The dose-response 
curves of drysdalin with the 3 AChBPs are plotted (Figure 3.6). The 
dissociation constants for Ls-, Ac- and AcY55W-AChBPs was determined to 
be 49.5 nM, 6.9 nM and 20.4 nM, respectively. The Hill coefficient of 









Figure 3.6 Dissociation constants of drysdalin binding to acetylcholine 
binding proteins and its mutant 
Representative titration profiles for drysdalin in competition with [3H] 
epibatidine, in comparison to α-bungarotoxin and α-cobratoxin, for ligand 
binding to (A) Ls-, (B) Ac-, (C) AcY55W-AChBP. Measurements were carried 
out by a scintillation proximity assay and are reported as an average of at least 
three individual experiments (±S.E). Nicotine is used as a positive control. 
Drysdalin is shown as dashed line. 
 
 Ligand binding to Ls vs Ac vs AcY55W 
Ls- and Ac- AChBP share only 33% sequence homology. A nest of aromatic 
amino acids form a hydrophobic ligand binding pocket in both AChBPs. The 
ligand binding pocket is made of 3 Tyr and 2 Trp in case of Ls-AChBP, 
whereas in case of Ac-AChBP it is made of 4 Tyr and only one Trp. Thus, the 
difference is the presence of W53 in Lymnaea when compared to Y (55 
corresponding to Aplysia) (Figure 3.7). Binding of small agonist such as 
nicotine, acetylcholine and epibatidine is about 10-fold less in Aplysia 
compared to Lymnaea. Long chain α-neurotoxins Bgtx and Cbtx bind to 
Lymnaea better than to Aplysia (Hibbs et al., 2004). This is consistent with my 
observation that binding of Bgtx and Cbtx is about 44- and 17.4-fold less to 
Ac-AChBP when compared to Ls-AChBP. In contrast to this, drysdalin has 
higher binding (7-fold) to Ac-AChBP when compared to Ls-AChBP. This 
clearly suggests the interaction of different set of residues of drysdalin and 
receptor for their interaction. This could be due the difference in the ligand-
binding pocket being presence of W53 in Lymnaea when compared to Y55 in 
Aplysia. Also the difference in the residues in drysdalin (Arg30, Leu34, 





Figure 3.7 Aromatic pocket with agonist bound to AChBP 
(A) Aplysia and (B) Lymnaea AChBP as viewed at the ligand binding site. 
Try55 in A occupies the same space and orientation as Trp53 in B. Figure 







Drysdalin inhibits ACh-evoked currents in Xenopus oocytes expressing 
muscle mouse αβεδ-nAChRs and human α7-nAChRs, similar to the long-
chain α-neurotoxins. Drysdalin also blocked the epibatidine responses in α7-
nAChR CNiFERs, indicated by the decrease in the Ca2+ influx into the cells. 
Further, drysdalin binds to the soluble AChBPs with different affinities to Ls- 
and Ac-AChBP.  
Despite the lack of functionally conserved residues required to bind nicotinic 
acetylcholine receptors and AChBP, drysdalin shows nanomolar affinity. 
Thus, drysdalin is a novel and potent antagonist to the nAChRs. Could the 
potency increase if drysdalin has the functionally conserved residues? This 
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Mutation studies have also been adopted to study the protein stability and 
folding (Lorch et al., 1999), protein function (Yamada et al., 2006), protein-
protein interactions (Ung et al., 2006) as well as protein expression and 
subcellular localization (Weiss et al., 2003). Functional studies by site-directed 
mutagenesis have identified the sites with which α-cobratoxin interacts with 
Torpedo muscle receptor (Antil et al., 1999) and α7 receptor (Antil-Delbeke et 
al., 2000). Similarly, the functional role of positively charged amino acid side 
chains in α-bungarotoxin binding to muscle nAChRs has been studied by site-
directed mutagenesis (Rosenthal et al., 1999). 
In addition to the above, mutation studies for the gain of function of protein 
and change of receptor selectivity have been widely explored. Grafting the 
central loop of a neuronal nicotinic toxin on the scaffold of a muscular-type 
toxin confers to it an improved neuronal activity (Mourier et al., 2000). 
Double mutation K38P, L42Q of α-bungarotoxin alters its receptor specificity 
from α7 to α3β2 neuronal receptors (Levandoski et al., 2000).  
In chapter 3, we established that drysdalin, despite the lack of key functional 
residues (Arg30, Leu33, Ala36), is a potent antagonist to nAChRs. We 
hypothesized that replacing residues to conserved residues (Phe30, Arg33, 
Arg36 numbered according to α-cobratoxin sequence) would increase the 
affinity of drysdalin.  Thus, site-directed mutagenesis of drysdalin was 
performed with an aim to increase affinity to nAChRs. We designed three 
single mutants (R30F, L34R and A37R), three double mutants (R30F,L34R; 
L34R,A37R; and R30F,A37R), one triple mutant (R30F,L34R,A37R). Apart 
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from these residues, previous mutation studies have also indicated the 
importance of C-terminal residues in long chain α-neurotoxins (Rosenthal et 
al., 1999). Thus, to understand the role of C-terminus residues of drysdalin in 
binding to the receptors a truncation mutant was also designed (20 residues 
removed from the C-terminal). 
All these mutants were recombinantly expressed, purified and refolded as the 
wild-type drysdalin. The effect of the mutations was tested on muscle, 




 Materials and methods 
 Reagents and kits 
Most the chemicals used in the experiments conducted for the mutants are as 
described in Chapter 2 and 3. Apart from the already mentioned chemicals, 
KAPA HiFi PCR kit (Kapa Biosystem, Cape Town, South Africa), restriction 
enzymes DpnI, BamHI (Fermentas Fast Digest, Ontario, Canada), DNA oligos 
for amplification (1st Base Asia, Singapore), DNA Gene ruler (Fermentas, 
Ontario, Canada) , plasmid extraction kit (GeneAll plasmid miniprep kit, 
Korea), Big Dye (Life Technologies, Carlsbad, USA) was also used. 
 Site directed mutagenesis 
Primers used for the generation of all the mutants along with the annealing 
temperatures are mentioned in the table below. 
Table 4.1 Primers for mutant generation 
Mutant Template plasmid 
Forward 
primer 
 (5’to 3’) 
Reverse primer 
 (5’to 3’) 
Annealing 
temperature 
































R30F,L34R pET-M with drysdalin 
Same as for 
L34R 






Same as for 
R30F 








Same as for 
A37R 
Same as for 
A37R 75°C 






Same as for 
R30F 75°C 
 
The 50 μl of PCR mix contained 1 μl (< 20ng) od template plasmid, 0.2 mM 
dNTPs, 0.2 μM of both forward and reverse primers, HiFi buffer at 1 X final 
concentration and 1 μl of polymerase. Three-step thermal cycling involved: 
95°C /3 min followed by 25 cycles of 98°C/20 s (denaturation), T°C/20 s 
(annealing), 72°C/4 min (extension) and a final extension of 72°C/5 min. The 
PCR product was run on 1% agarose gel to check for amplification. The 
plasmid was digested with DpnI restriction enzyme (which cuts the methylated 
template DNA) by incubation at 37°C for 15 min. This mix is then used for 
transformation in JM109 cells. The recombinant plasmid is then confirmed by 
sequencing the plasmid.  
 Protein expression, purification and refolding of the mutants 
The protein expression, purification and refolding of all the mutants were done 
as described in Chapter 2. 
 Characterization of the mutants 
Structural characterization by secondary structure determination by CD 
spectroscopy; functional characterization by electrophysiology experiments 
with Xenopus oocytes expressing mouse muscle and human α7-nAChRs, Flex 
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assay with human α7 CNiFERs and radioligand binding assay with AChBPs 




 Results and discussion 
 Site-directed mutagenesis 
All the mutants were generated by site-directed mutagenesis, where the 
primers having the mutations were used for the amplification of wild-type 
pET-M with drysdalin. At the optimized annealing temperatures, most of the 
DNA amplified is the desired plasmid DNA with very little non-specific 
amplification (Figure 4.1). 
 
Figure 4.1 Gel electrophoresis of the PCR amplified mutant vectors 
The amplified mutant plasmid migrates around 5000 bp which is the size of 




 Expression, purification and refolding of the mutants 
The optimized conditions for expression of all the mutants are induction with 
1 mM IPTG followed by incubation at 37 °C for 4 h. They were purified, 
refolded similar to wild-type drysdalin. The refolded protein is purified to 
homogeneity using an analytical column. The ESI-MS shows mass similar to 
the calculated mass (Appendix A.4). 
 Secondary structure of the mutants 
The CD spectrum of the mutants shows a minimum at 206-209 nm and a 
maximum around 195 nm (Appendix A.5). This indicates that they have a 
proper fold with a secondary structure mainly composed of β-sheets. 
 Effect of drysdalin mutants on mouse αβεδ-nAChRs expressed on 
Xenopus oocytes 
Xenopus oocytes expressing mouse muscle αβεδ-nAChRs were challenged 
with various concentrations of drysdalin mutants to test their ability to inhibit 
ACh-evoked currents. Drysdalin mutants (0.3-1000 nM; n=3-4) were able to 
inhibit the currents in a dose-dependent manner. The inhibition dose-response 
curves are plotted and the IC50 values are determined (Figure 4.2). The fold-
increase in IC50, reflects the fold-decrease in inhibition activity for the 
mutants, is calculated in comparison to wild type drysdalin (Table 4.2). The 
mutation R30F showed a 4.4-fold decrease, whereas the mutations L34R, 
A37R show a 2-fold increase in the activity. The double mutations 
R30F,L34R and R30F,A37R show less than 5-fold decrease, whereas 
L34R,A37R show a 3-fold increase in activity. The effect of the three 
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mutations R30F,L34R,A37R is seen as a 1.6-fold increase in activity. The 
truncation of the 18 residues from the C-terminus caused a 5.8-fold reduction 
in activity. The inhibition curves of the mutants were adequately described by 
a single Hill equation with Hill coefficients (nH) ranging from 0.9-1.7, with 
the exception of double mutant R30F,A37R (nH=2.3). Hill coefficient of 1 













Figure 4.2 Effect of drysdalin and its mutants on mouse αβεδ-nAChRs 
expressed on Xenopus oocytes 
(A), (B), (C), (D) Inhibition curves of the normalized data, IC50 and Hill 
coefficient (nH) of single, double mutants, triple, truncated mutant of 
drysdalin are determined, respectively. Each data point is the mean ± SEM of 
minimum of 3 experiments. 
 
Table 4.2 Comparison of IC50 values of drysdalin and its mutants on 
mouse αβεδ-nAChRs 
 
Antagonist IC50 ± SEM (nM) Fold 
difference 
Drysdalin 16.9 ± 3.6 1.0 
R30F 74.6 ± 6.7 4.4 
L34R 9.1 ± 1.1 0.54 
A37R 7.9 ± 0.8 0.46 
R30F, L34R 45.1 ± 10.3 2.7 
R30F, A37R 73.7 ± 12 4.4 
L34R, A37R 5.7 ± 1.5 0.34 
R30F, L34R, A37R 10.7 ± 1.2 0.6 
TD 97.6 ± 14 5.8 
Bgtx 13.96 ± 1.7 0.8 





Effect of single mutations  
The Phe-substitution of Arg30 was made with an aim to increase the affinity 
of drysdalin towards mouse αβεδ-nAChRs. It is established that Phe at this 
position in long-chain α-neurotoxins play an important role in binding to the 
receptor (Nirthanan and Gwee, 2004). This is revealed by the mutation studies 
as well as in the co-crystal structures of toxins with receptor subunits. Studies 
on α-cobratoxin show that the mutations Phe29Leu/Trp/Ala, cause a decrease 
in binding to Torpedo receptor by a factor of 12.4/1.29/3 (Antil et al., 1999). 
Further, it has been seen in the co-crystal structure of α-Cbtx with Ls-AChBP 
that Phe29 and Arg33 side chains are well positioned for establishing 
hydrophobic and aromatic interactions with AChBP Trp53, Tyr185, Tyr192, 
and Trp143, in the ligand-binding pocket (Bourne et al., 2005). This has also 
been observed at the ligand-binding pocket of mouse α1 subunit, wherein 
Phe32 and Arg36 of Bgtx loop II and Tyr198, Tyr190 and Tyr93 of α1 subunit 
forms an elaborate cation-π interaction system (Figure 4.3) (Dellisanti et al., 
2007).   
In drysdalin the mutation R30F caused a 4.4-fold decrease in affinity to mouse 
muscle receptor. In the view of importance of Phe at this position this decrease 
is contrary to what we expected. It may be explained by the loss of the 
guanidinium group of Arg which is known to form cation-π interaction with 
aromatic amino acids (Dougherty, 2007). Interaction of Arg with Tyr was 
found to be the most abundant, among different classes of protein-protein 
interfaces (homo-dimer, hetero-dimer, protein complex, crystal packing) 
(Crowley and Golovin, 2005). Since the ligand-binding pocket of mouse 
muscle nAChRs is formed by aromatic amino acids like Tyr and Trp, we 
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speculate that the Arg30(drysdalin) is involved in the cation-π interaction at 
the ligand-binding pocket. And the loss of this interaction is causing a 
decrease in the inhibition activity of drysdalin.  
 
The mutation L34R was made with an aim of increasing the activity of 
drysdalin to mouse muscle nAChR. The importance of Arg at the homologous 
position in other long chain α-neurotoxins is well known. Mutation studies 
wherein Ala-substitution of Arg36 in Bgtx causes a 90-fold decrease in 
binding to mouse muscle nAChRs, demonstrates that Arg36 side chain plays a 
critical functional role in long-chain neurotoxins (Rosenthal et al., 1999). A 
decrease of 767-fold affinity to Torpedo receptor was observed when 
Arg33Glu mutation was made in Cbtx (Antil et al., 1999). Further this is 
supported by the studies of co-crystal structures of toxin with the receptors, 
wherein Arg33(Cbtx) and Arg36(Bgtx) are thought to be involved within the 
aromatic ligand binding pocket as described above. Replacing the hydrophobic 
side chain of Leu with a cationic side chain of Arg, drysdalin gained function 
by 2-fold. Thus, the change from hydrophobic interactions to cation-π 
interactions may have caused the increase in drysdalin activity. 
 
Similarly mutation A37R was made with an aim to increase the activity of 
drysdalin. The importance of Arg at the homologous position in Cbtx is 
confirmed by the mutation Arg36Ala which resulted in a 7.4-fold decrease in 
binding to Torpedo receptor (Antil et al., 1999). As inferred from the crystal 
structure of Bgtx-mouse α1 subunit complex, Val39 (Bgtx) along with other 
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residues in loop II is involved in possibly hydrophobic interactions with 
residues of loop A and C in the receptor (Dellisanti et al., 2007). 
The mutation A37R in drysdalin showed an increases in affinity by 2-fold, 
which due to increased hydrophobicity of the side chain, could contribute to 
the hydrophobic interactions the receptor. 
 
Figure 4.3 Binding of α-bungarotoxin to extracellular domain muscle α1 
nAChR 
Detailed view of the interactions at the aromatic cage. Here Tyr198 of nAChR 
α1 and Arg36 and Phe32 of Bgtx stack face-to-face, whereas Tyr190 and 
Tyr93 of nAChR α1 and Arg36 and Phe32 of Bgtx stack edge-to-face. 
 
Effect of double and triple mutations  
As previously mentioned, single mutations R30F, L34R, and A37R in 3 
possible combinations were used to construct double mutants i.e. R30F,L34R; 
R30F,A37R; and L34R,A37R. A triple mutant with all 3 single mutations was 
also constructed. These mutants were made to test if any of the mutation 
combination would increase drysdalin’s activity to mouse muscle nAChR.  
The double mutant R30F,L34R shows a 2.7-fold decreased affinity to mouse 
muscle nAChR. As explained earlier the mutation R30F shows a decrease, 
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whereas mutation L34R shows an increase in activity of drysdalin. When these 
2 mutations are combined, we see a decrease in activity which could be 
explained by the gain of function for mutant R30F in combination to L34R.  
Also the residues at these positions may mimic the Phe32, Arg36 of Bgtx in 
the cation-π interaction system (Figure 4.3).  The double mutant R30F,A37R 
(4.4-fold decreased affinity) binds similar to the mutant R30F, indicating that 
mutation to Arg37 may not contribute significantly to the toxin receptor 
interactions. The double mutant L34R,A37R (3-fold increased affinity) binds 
better than the single mutants L34R and A37R, indicating that both mutant 
Arg contributes towards toxin reception interactions.  The triple mutant shows 
1.6-fold increased affinity to mouse muscle nAChR, indicating that the Arg34, 
37 restores the affinity to mouse muscle nAChR in the single mutant R30F. 
Role of C-terminal tail  
The truncation of the C-terminus residues showed a 5.8-fold decrease in 
affinity. The importance of C-terminal tail in binding to the receptors is well-
known. In Bgtx the His68 and Pro69 at the C-terminus forms a sandwich-like 
hydrophobic interaction with Pro194 (α1 subunit), as seen in the crystal 
structure of the complex (Figure 4.4). Removal of the seven carboxyl-terminal 
residues HPKQRPG in Bgtx caused a 7-fold decrease in binding to Torpedo 
receptor (Rosenthal et al., 1999). Also the Ala mutation of Phe65 (Cbtx) 
shows a 6.8-fold decrease in affinity to Torpedo receptor (Antil et al., 1999).  
The tail of drysdalin is 24 residues long, as compared to 9 residues in Bgtx and 
Cbtx. It is rich in Pro and Arg, which may contribute towards the hydrophobic 
interactions with the receptors. However, the cation-π interactions that Arg can 
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form with other aromatic residues outside the ligand binding site cannot be 
ruled out, owing to the length of the C-tail. Thus, the loss of the C-terminal 
residues in drysdalin causes a significant loss in its binding. 
 
 
Figure 4.4 Interaction of C-terminus residues of Bgtx 
Zoomed in view of the interactions at the loop II of Bgtx. Here His68 and 
Pro69 interact with the Pro194 of the receptor interface. Bgtx is shown in 
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 Effect of drysdalin mutants on human α7-nAChRs expressed on 
Xenopus oocytes 
Xenopus oocytes expressing human α7-nAChRs were challenged with various 
concentrations of drysdalin mutants. Drysdalin mutants (0.3-1000 nM; n=3-5) 
were able to inhibit ACh-evoked currents in a dose-dependent manner. The 
inhibition dose-response curves were plotted and the IC50 values were 
determined (Figure 4.5). The fold difference in IC50, reflects the fold-decrease 
(> 1) or increase (< 1) in affinity for the mutants, is calculated in comparison 
to wild-type drysdalin (Table 4.3). The mutation R30F shows 18.8-fold 
decrease, whereas the mutations L34R and A37R show a slight decrease in the 
activity (< 2-fold). The double mutations R30F,L34R and R30F,A37R show 
less than 6-fold decrease, whereas L34R,A37R and triple mutant show 1.2 to 
1.7-fold decrease in activity. The truncation mutant caused a 2-fold decrease 
in activity. The inhibition curves of the mutants were adequately described by 













Figure 4.5 Effect of drysdalin and its mutants on human α7-nAChRs 
expressed on Xenopus oocytes 
 A), (B), (C), (D) Inhibition curves of the normalized data, IC50 and Hill 
coefficient (nH) of single, double mutants, triple, truncated mutant of 
drysdalin are determined, respectively. Each data point is the mean ± SEM of 
minimum of 3 experiments. 
 
Table 4.3 Comparison of IC50 values of drysdalin and mutants on human 
α7-nAChRs 
Antagonist IC50 ± SEM (nM) Fold 
difference 
Drysdalin 9.98 ± 0.6 1.0 
R30F 188 ± 23.8 18.8 
L34R 13.2 ± 1.4 1.3 
A37R 14.1 ± 1.5  1.4 
R30F, L34R 65 ± 10 6.5 
R30F, A37R 23.6 ± 3.1 2.4 
L34R, A37R 11.7 ± 1.6 1.2 
R30F, L34R, A37R 17.1 ± 2.6 1.7 
TD 19.5 ± 2.1 1.96 
Bgtx 5.6 ± 0.7 0.57 





Effect of single mutations  
The Phe-substitution of Arg30 was made with an aim to increase the affinity 
of drysdalin towards human α7-nAChRs. The Phe at the homologous positions 
in long chain α-neurotoxins is important for binding to α7 receptor as shown 
by mutation studies and co-crystal structure of toxin and receptor. The 
mutation Phe29Ala in Cbtx resulted in a 74-fold reduction in affinity to α7/5-
HT3 receptor (Antil-Delbeke et al., 2000). It has been seen in the co-crystal 
structure of Bgtx with α7 ligand-binding domain chimera, that Phe32 and 
Arg36 (loopII of Bgtx) form a cation-π stack, which aligns edge-to-face with 
the aromatic ring of Tyr184 from the loop C of the receptor (Figure 4.6) (Sun 
et al., 2013). Arg36 also forms hydrogen bonds with the hydroxyl group of 
Tyr91 of loop A and the main-chain carbonyl group pf Trp145 of loop B 
(Figure 4.6).  
 
Figure 4.6 Inter-residue interactions between α-btx and the α7/AChBP 
chimaera 
Stereo view of key residue side chains between the tip of finger II of α-btx 
(purple) and the principal subunit of the α7/AChBP chimaera (cyan). Adopted 




In drysdalin mutation R30F showed 18.8-fold decrease in affinity for the 
human α7-nAChR. In the view of the importance of Phe at this position, as 
established above, the decrease is contrary to expected. This decrease can be 
explained by the loss of the interactions that Arg30 might have with the 
aromatic residues of the receptor. Guanidinium group of Arg30 could be 
involved in the cation-π interactions and/or aliphatic chain of Arg could be 
involved in hydrophobic interactions within the aromatic ligand binding site. It 
appears that loss of these interactions have resulted in the loss of drysdalin’s 
activity to human α7-nAChRs. 
We observe a 1.3-fold decrease in activity for the mutation L34R. The 
importance of Arg at the homologous position in other long chain α-
neurotoxins is well known. Mutation studies of Cbtx show a decrease of 339-
fold affinity to α7-receptor when Arg33 was replaced with Glu (Antil-Delbeke 
et al., 2000; Antil et al., 1999). Further this is supported by the studies of co-
crystal structures of toxin with the receptors, wherein Arg36(Bgtx) are thought 
to be involved within the aromatic ligand binding pocket as described above. 
Replacing the hydrophobic side chain of Leu with a cationic side chain of Arg, 
drysdalin loses its affinity by 1.3-fold. Since this change is not significant we 
speculate that Leu is involved in hydrophobic interactions with the receptor 
residues. Thus, the change from Leu to Arg, which does not change the 
hydrophobicity significantly, has little effect on the activity of drysdalin. 
Similarly mutation A37R does not cause a significant reduction in affinity. 
This is contrary to what we expected increase because the Ala-substitution of 
Arg36 at the homologous position in Cbtx results in a 16-fold decrease in 
binding to α7 receptor highlighting its importance (Antil-Delbeke et al., 2000).  
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Thus, the change from Ala to Arg, which does not change the hydrophobicity 
significantly, has little effect on the activity of drysdalin. 
Effect of double and triple mutations  
The double mutations R30F,L34R and R30F,A37R show less than 6-fold 
decrease, whereas L34R,A37R and triple mutant show 1.2 to 1.7-fold decrease 
in activity. 
Role of C-terminal tail  
The truncation mutant showed a 2-fold decrease in affinity to human α7-
nAChR. The importance of C-terminal tail in binding to the neuronal receptors 
is well-known. In Bgtx the His68, Pro69, Lys70 at the C-terminus interact 
with the main chain and side chains of Glu185, Cys186, Cys187 at the tip of 
the loop C of the α7 receptor, as seen in the crystal structure of the complex 
(Figure 4.7) (Sun et al., 2013). The importance of the C-tail is also supported 
by the mutation studies of Cbtx. Ala-substitution of Phe65 and Pro66 result in 
a 15.5- and 2.7-fold decrease in affinity to α7 receptor. The truncation mutant 
Δ66 result in a 3.3-fold decrease in affinity.  
The truncation mutant of drysdalin is made in such a position that it retains the 
Phe and Pro at the homologous positions. Inspite of the presence of these 
residues in the C-terminus of drysdalin it shows reduced affinity. This would 
lead us to believe that C-terminus residues in drysdalin contributes towards its 
binding to human α7-nAChRs.The tail of drysdalin is 24 residues long, as 





Figure 4.7 Interaction between C-terminal residues of Bgtx and the 
α7/AChBP chimaera 
Stereo view of key residues between finger I of Bgtx (purple) and the backside 
of loop C of the α7/AChBP chimaera (cyan). Figure adopted from (Sun et al., 
2013) 
 
 Effect of drysdalin mutants on α7-nAChR CNiFERs 
 
Ca2+ sensing HEK cells expressing human α7-nAChR were challenged with 
various concentrations of drysdalin mutants. Drysdalin at 100 nM completely 
blocked the epibatidine responses from the α7-nAChR CNiFERs (Figure 4.8). 
Varying concentrations of drysdalin mutants (0.3- 1000 nM) showed a dose-
dependent blockage of the epibatidine elicited responses in the α7-nAChR 
CNiFERs. An inhibition dose-response curve was plotted and EC50 values are 
determined. In this assay too, drysdalin shows only 4-fold less activity when 
compared to Bgtx and similar affinity compared to Cbtx. This is in contrast to 
the lack of the functionally important residues in drysdalin. This suggests that 
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Figure 4.8 Effect of drysdalin mutants on human α7-nAChR CNiFERs 
Competitive blockage of the epibatidine elicited responses on α7-nAChR 
CNiFERs by drysdalin mutants is plotted as normalized response. Each data 
point is the mean ± S.E of minimum of 3 experiments. Drysdalin is shown as a 
dashed line. 
 





Antagonist EC50 ± S.E (nM) Fold 
difference 
Drysdalin 8.5 ± 0.4 1.0 
R30F 152.6  18 
L34R 31.1 ± 5.2 3.7 
A37R 8.17 ± 1.8 1.0 
R30F, L34R 8.19 ± 2.2  1.0 
R30F, A37R 4.8 ± 1.12 0.6 
L34R, A37R 9.65 ± 2.6 1.1 
R30F, L34R, A37R 3.74 ± 1.01 0.4 
TD 756 ± 38.9 89 
Bgtx 2.05 ± 0.7 0.2 
Cbtx 7.4 ± 1.1 0.9 
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 Effect of drysdalin mutants on the binding to Ac-AChBP 
Drysdalin mutants were screened for their ability to compete or interfere with 
the binding of [3H] epibatidine to Ac- AChBPs as measured by a scintillation 
proximity assay. Nicotine, a known ligand for AChBPs, is used as a positive 
control showed significant interference for the binding of [3H] epibatidine. 
A scintillation proximity assay was employed to measure the ligand binding. 
Varying concentrations of drysdalin mutants (0.3 nM- 10 μM, n=3) were 
incubated with the Ac-AChBP and the competing ligand [3H] epibatidine. The 
dose-response curves of drysdalin mutants with the Ac-AChBPs are plotted 
and dissociation constants determined (Figure 4.9; Table 4.5). The Hill 
coefficient of drysdalin mutants binding to the Ac-AChBPs was between 0.7-
1.0. Mutation R30F and truncation of C-terminal residues cause ~100-fold 
decrease in the binding of drysdalin to Ac-AChBP. Only mutant A37R show 
2.5-fold increase, whereas the other single, double and triple mutant shows 
















Figure 4.9 Dissociation constants of drysdalin and its mutant in binding to 
acetylcholine binding proteins and its mutant 
Representative titration profiles for (A) single, (B) double, (C) triple, (D) 
truncation mutants in competition with [3H] epibatidine for ligand binding to 
Ac-AChBP, in comparison to wild-type drysdalin. Measurements were carried 
out by a scintillation proximity assay and are reported as an average of at least 
three individual experiments (±S.E). Nicotine is used as a positive control. 
Drysdalin is shown as dashed line. 
 
Table 4.5 Dissociation constants of drysdalin and mutants with Ac-
AChBP 
Antagonist Kd ± S.E (nM) Fold 
difference 
Drysdalin 6.9 ± 0.5 1.0 
R30F 688 ± 46.2 99.6 
L34R 39.3 ± 6.8 5.7 
A37R 2.5 ± 0.17 0.4 
R30F, L34R 97.3 ± 6.3 14.1 
R30F, A37R 245 ± 13.6  35.4 
L34R, A37R 8.2 ± 0.54 1.2 
R30F, L34R, A37R 48.7 ± 9.3 7 
TD 612 ±  33.5 88.5 
Bgtx 91.6 ± 0.13 13.3 





The mutation studies on drysdalin were conducted in order to improve its 
function as a potent antagonist. We observe that cation-π interactions that 
Arg30 (drysdalin) may form with the aromatic amino acids in the ligand 
binding pocket of the receptor is very important. The loss of this interaction 
caused a significant decrease in its activity. The mutations of other residues 
(Leu34 and Ala37) of drysdalin to Arg do not cause a significant increase of 
decrease in the activity of drysdalin. This may be because of the hydrophobic 
interactions being important at these positions to bind to the receptor. 
The importance of C-terminus residues is once again reinforced in 3FTxs. In 
all the assays the truncation mutant showed significant reduction in the 
activity of drysdalin. Despite the presence of Phe and Pro in the truncation 
mutant, it showed loss in the activity suggesting that other residues too have a 
role in the toxin’s binding to the receptor. 
Thus, we could increase the activity of drysdalin towards mouse muscle 



















 Future directions 
 Immediate milestones 
The first part of this thesis is the characterization of a novel three-finger 
neurotoxin and the second part is the study of drysdalin and mutants 
interaction with various nicotinic acetylcholine receptors. They were few 
interesting observations made during the course of the experiments which are 
worth discussing here. 
 Kinetic studies of drysdalin with Ac-AChBP 
Stopped-flow measurements for ligand association (kon) and dissociation (koff) 
kinetics were conducted using the Applied Photophysics SX.18MV 
(Leatherhead, UK) stopped-flow spectrofluorometer. The Ac-AChBP was 
excited at 280 nm, and a 305 nm cut-on filter was used to select the 
fluorescence signal. Different concentration of drysdalin was mixed with 100 
nM of Ac-AChBP for the kon studies. Rates of association and dissociation 
were estimated from the slope and ordinate intercept of plots of overall rate of 
fluorescence change versus ligand concentration (Figure 5.1) which showed 
slow rate of association (kon is 0.02 * 10^8 M-1s-1) and dissociation for 
drysdalin. Dissociation rate was estimated by reacting the preformed complex 
with a large excess of gallamine in the stopped-flow instrument and observing 
the time course of the increase in fluorescence. But probably because of the 
extremely slow dissociation, the readings were not accurate. Hence other 
methods using fluorescent plate readers should be employed to measure the 




Figure 5.1 Kinetic of ligand association of drysdalin with Ac-AChBP 
Different concentrations of drysdalin was mixed with 100 nM of Ac-AChBP. 
Excitation was at 280 nm and a cut-off filter at 305 nm was used on the 
emission side. The first order rate constant kobs was plotted against ligand 
concentration. The individual rate constants were obtained from kobs = k1[L] 
+ k-1, where k1 is the slope (kon) and k-1 the ordinate intercept (koff). 
 
 Reversibility of truncated drysdalin 
Drysdalin and the single, double, triple mutants tested showed irreversible 
binding to Xenopus oocytes expressing mouse αβεδ and human α7 nAChRs, 
after washout in the TEVC experiments. Interestingly, truncated drysdalin 
restored the current to the maximum even after the addition of the highest 
concentration tested (300nM). This reversibility was seen for the 
nAChRs.  This observation needs to be confirmed by repeating the 
experiment, which are currently ongoing in our collaborator’s lab. We are 
tempted to propose that the C-terminal resides are important in anchoring the 
toxin to the receptor and orienting the residues in the 3 fingers towards and 
into the ligand-binding pocket of the receptor. However, these can be 
confirmed by co-crystallization studies. 
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Structural studies of drysdalin 
To better understand the spatial arrangement of the key residues in drysdalin 
and also the C-terminal residues, crystallization studies are being performed. 
Hanging drop method is chosen as the preferred method for setting the 
crystals. Crystals at 20mg/ml (at room temperature) and 40 mg/ml (at 4 °C) 
were set with Hampton crystal screen I and II. The plates were observed for 
crystal formation every 2 days for the first week and subsequently once every 
week. No crystals formed up to 2 months after crystal set-up. More conditions 
for crystallization should be tried. 
 Co-crystallization of drysdalin with Ac-AChBP 
Nicotinic acetylcholine receptors are important pharmaceutical targets for 
many human diseases, such as epilepsy, schizophrenia, depression and 
substance addiction. A central question regarding the function of nAChRs is 
how ligand binding is coupled to channel gating (Changeux and Edelstein, 
1998). Though extensive biochemical and electrophysiology analyses have 
provided a wealth of information about the roles of specific residues in ligand 
binding and channel function, the exact mechanism by which the 
neurotransmitter induces conformation change required for channel gating is 
not yet known (Sine and Engel, 2006). This is partially due to the lack of 
direct high-resolution structural data for nAChR. 
AChBP, which is a homologue of extracellular domain of nAChRs, has been 
crystallized with small molecules like HEPES, nicotine, acetylcholine, 
carbachol. But, currently there is only one co-crystal structure of α-neurotoxin 
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Cbtx, with Ls-AChBP (Bourne et al., 2005) giving insights into the toxin 
receptor interaction interface. Currently, there is no structure available of α-
neurotoxin with Ac-AChBP. Since drysdalin binds to Ac-AChBP with 
nanomolar affinity, we are currently trying to crystallize the complex. This 
would also give us insights as to how drysdalin binds to the receptor and if the 
C-terminus residues are involved in the interaction. 
 Big picture 
Mutation studies to develop a subtype-specific antagonist 
Nicotinic acetylcholine receptors (nAChRs) play important roles in several 
neuro-pathologies. Highly selective ligands help in understanding the 
distribution and physiological roles of nAChRs, many of which are not yet 
clear. There is a lack of ligands which show subtype selectivity. Snake venom 
is an excellent source of such natural nAChR antagonists. One such potent 
antagonists “Drysdalin” is characterized in our study. Drysdalin shows 
nanomolar affinity to muscle and neuronal nAChRs. Our mutation studies 
reveal that Arg30 and 20 residues at the C-terminus are critical for its function, 
along with hydrophobic amino acids at positions 34 and 37. Using this 
information we propose further studies whereby we propose the mutations at 
positions 34 and 37 to hydrophobic residues like Trp, Tyr, Phe, Met. Further 
we propose mutations K24E and K50E, with a aim to decrease the affinity to 
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Appendix A.1 Vector map of pET-M 
The sequences marked in yellow are removed from pET-32a vector to 











Appendix A.2  Tris-Tricine gel composition (for 2 gels) 
Stock solutions Resolving gel 
 (15%) 




5 ml 0.666 ml 
3 X Gel buffer  (3 M Tris-Cl, 0.3% 
(w/v) SDS, pH 8.45) 
3.333 ml 1.666 ml 
90% Glycerol 1 ml -- 
Water 0.567 ml 2.613 ml 
10% APS (freshly prepared) 100 μl 50 μl 
TEMED 10 μl 5 μl 
Total Volume 10 ml 5 ml 
 
Running buffer (To be used at 1 X concentration) 
10 X Anode buffer 10 X Cathode buffer 
1 M Tris-Cl, pH 8.9 1 M Tris 
 1 M Tricine 
 1% (w/v) SDS 
 pH adjustment not required 
 
Destaining solution: Methanol: Acetic acid: Water = 40: 10: 50 
























Make aCSF 1L     
  MW gram/L 
121mM NaCl 58.5 7.07 
5mM KCl 74.6 0.37 
26mM NaHCO3 (sodium Biocarbonate) 84 2.18 
1.2mM NaH2PO4.H2O (monobasic 
monohydrate) 137.99 0.166 
10mM Glucose 180 1.8 




































Appendix A.5 CD spectrum of mutants of drysdalin 
CD spectrum of (A), (B), (C), (D) single, double mutants, triple and truncated 
mutant in comparison to drysdalin 
 
 
 
 
